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resumo 
 
 
O presente relatório descreve as atividades desenvolvidas durante o estágio 
curricular como coordenadora de investigação clínica, que teve lugar na 
Unidade de Farmacologia Clínica do Instituto de Medicina Molecular e 
decorreu de Setembro de 2014 a Junho de 2015.  
A principal atividade desempenhada durante este estágio foi a coordenação de 
ensaios clínicos na área da neurologia, nomeadamente ensaios de fase II, III e 
IV. Foram desenvolvidas outras atividades, tais como gestão de dados 
clínicos, atividades de farmacovigilância e escrita científica e monitorização de 
estudos clínicos, com vista a complementar a formação curricular.  
Neste relatório é, também, apresentada uma breve contextualização do estado 
de arte do processo de Investigação & Desenvolvimento de novos 
medicamentos, tendências atuais e especificidades do desenvolvimento de 
medicamentos na área da neurologia. Para além disso são abordadas as 
dificuldades sentidas durante o estágio e as estratégias utilizadas para as 
ultrapassar, bem como a visão pessoal sobre o papel do coordenador de 
investigação clínica na condução de ensaios clínicos.  
Globalmente, a realização deste estágio curricular traduziu-se na oportunidade 
de aplicar e aprofundar os conhecimentos e competências adquiridos ao longo 
do percurso académico, em especial no Mestrado em Biomedicina 
Farmacêutica, e de desenvolver competências e aptidões, tanto a nível 
profissional como pessoal, fulcrais para um profissional de investigação clínica. 
Em conclusão, este estágio constituiu uma introdução à prática da 
investigação clínica. 
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abstract 
 
This report describes the activities developed during the curricular training as 
coordinator of clinical research, which took place in the Unidade de 
Farmacologia Clínica of the Instituto de Medicina Molecular and was held from 
September 2014 to June 2015.  
The main activity performed during this training was the coordination of clinical 
trials in the field of neurology, mainly phase II, III and IV clinical trials. Other 
activities, such as data management, pharmacovigilance, medical writing and 
monitoring of clinical studies, were developed to complement the training. 
This report also presents a brief background of the state of the art of the 
Research & Development process of new drugs, current trends and 
specificities of the drug development in neurology. Furthermore, it addresses 
the difficulties experienced during the training and the strategies used to 
overcome them, as well as a personal insight on the role of the clinical research 
coordinator in conducting clinical trials.  
Overall, achieving this curricular training resulted in the opportunity to apply 
and deepen the knowledge and skills acquired throughout the academic career, 
especially in the Masters in Pharmaceutical Biomedicine, and to develop skills 
and abilities, at professional and personal level, central to a professional of 
clinical research. In conclusion, this training was an introduction to the practice 
of clinical research. 
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1. Introduction 
This curricular training report presents an overview of the activities performed 
as trainee in clinical trials coordination, from September 2014 to June 2015. This 
training was carried out within the scope of the Master’s degree in Pharmaceutical 
Biomedicine and took place at Unidade de Farmacologia Clínica (UFC, Clinical 
Pharmacology Unit), one of the research units of the Instituto de Medicina Molecular 
(IMM, Institute of Molecular Medicine), an associate laboratory of the Portuguese 
Ministry for Education and Science. 
During the training I had the opportunity to actively participate in several 
activities relating to different stages of the development of new health interventions, 
mainly new drugs, and to support others. These activities include not only coordination 
of clinical trials but also management of clinical data, writing of scientific papers and 
performance of pharmacovigilance activities, from the perspective of the regulatory 
authority. 
This report provides a characterization of the UFC, defining where it fits in the 
clinical research framework, its purposes, organization and work developed, followed 
by the identification of the objectives defined for this curricular training, and by an 
overview of the Research and Development (R&D) process of new drugs, highlighting 
the particularities of the R&D process in neurological diseases. The activities 
performed during this ten-month period are then described, with more emphasis for the 
activities of clinical trials coordination, as well as a brief theoretical overview on topics 
that contextualize the activities described. 
A discussion about the training experience and a summary of the importance of 
each of the activities performed to the successful planning, conducting, management 
and reporting of clinical projects, mainly clinical trials, are presented.  
 
 
1.1. Vision of the Host Institution 
The UFC is a research unit of IMM, a private, non-profit association mainly 
supported by national public funds and European Union (EU) funds that aims to foster 
basic, clinical and translational biomedical research to better understand diseases, 
contribute to the development of diagnostic and prevention tools and to develop new 
and efficient therapeutics (1). The unit was formally created on the 1st of July 2013 
based on the research team from the Unidade de Neurofarmacologia 
(Neuropharmacology Unit) of the Unidade Neurológica de Investigação Clínica 
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(Neurological Clinical Research Unit) of IMM and the members of the Laboratório de 
Farmacologia Clínica (Laboratory of Clinical Pharmacology) of Faculdade de Medicina 
da Universidade de Lisboa (Medicine Faculty of University of Lisbon) (2). 
As a research unit of IMM, the UFC shares with it its overall objectives. The 
UFC aims to contribute to the development of effective and safe therapeutic 
interventions through the establishment of optimized methodologies for the design, 
conduction, analysis and report of clinical trials (3). The research activity of UFC is 
focused on neurodegenerative diseases, particularly Parkinson's disease and 
Huntington's disease, specific populations, mainly late stage disease populations, and 
orphan interventions, such as rehabilitation and non-pharmacological interventions (3). 
The main clinical pharmacology domains of interest of the UFC are clinical trials 
methodology, with particular interest on novel, early phase proof-of-concept clinical 
studies and innovative trial designs and methodologies, outcomes, systematic reviews, 
drug safety and utilization and pharmaco-magnetic resonance imaging (4). The UFC 
establishes collaborations with the pharmaceutical industry to facilitate the conduction 
of clinical trials by supporting in early stages of drug development and planning of 
clinical development (4). Furthermore, the UFC is also committed to organize and 
provide comprehensive clinical pharmacology services to other research groups of the 
Centro Hospitalar Lisboa Norte (Hospital Center of North Lisbon), Faculdade de 
Medicina da Universidade de Lisboa and IMM, to educate and train in clinical trials 
methodology and Good Clinical Practice (GCP) and to foster investigator‐initiated trials 
(3). 
The research activity of the UFC is funded through participation in several 
national and international projects. During the period of 2014/2015, the UFC was 
involved in eight projects, most of them related to Parkinson's disease. Currently, the 
UFC integrates six different sub-units, as shown in Figure 1, that relate to each other 
and cooperate to achieve the overall objectives of the unit (3).  
 
 
 
 
 
Figure 1. Structure and organization of the UFC. Adapted from (3). 
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The Sub-Unidade de Outcomes (Outcomes Sub-Unit) is facilitated by Professor 
Joaquim Ferreira and co-facilitated by Dr. Ricardo Fernandes, a clinical researcher 
affiliated with the UFC, and is focused on the study of measurement instruments, 
including biomarkers and patient-reported outcomes, in drug evaluation (2). The Sub-
Unidade de Avaliação de Medicamentos e Revisões Sistemáticas (Drug Evaluation 
and Systematic Reviews Sub-Unit) is facilitated by Professor João Costa, Coordinator 
of the Centro Português Cochrane (Cochrane Portuguese Center) and Vice-Director of 
the Centro de Medicina Baseada na Evidência (Center of Evidence-Based Medicine) of 
the Faculdade de Medicina da Universidade de Lisboa. This research sub-unit 
corresponds to the Grupo Cochrane de Doenças do Movimento (Cochrane Movement 
Disorders Group) and its principal function is to create and maintain a register of trials 
in movement disorders to provide reviewers, facilitating the development of systematic 
reviews (2). The Sub-Unidade de Pharmaco-Magnetic Resonance Imaging (Pharmaco 
MRI Sub-Unit) is facilitated by Dra. Sofia Reimão, a clinical researcher affiliated with 
the UFC, and, through application of neuroimaging techniques, works to detect micro-
structural, functional and biochemical alterations in Central Nervous System (CNS) 
related to neurological diseases (4).  
The remaining research sub-units of UFC correspond to the sub-units where my 
curricular training took place. What follows is a detailed description, in chronological 
order according to the course of the training, of their objectives, constitution and main 
activities developed. 
 
1.1.1. Sub-Unidade de Bioestatística e Metodologia 
The Sub-Unidade de Bioestatística e Metodologia is a research sub-unit of the 
UFC that is focused on management of investigator driven research projects, statistical 
analysis of clinical data, medical writing, project management, and other support 
activities (4).   
This sub-unit provides statistical support to all research projects of the UFC, 
mainly those related with design and analysis of clinical trials and systematic reviews, 
as well as methodological support on design, conduction, analysis and reporting of 
clinical research studies, and optimization of study design and feasibility (2). The sub-
unit also provides logistical support to the vast majority of the projects of the UCF (2). 
The research group is facilitated by Professor Joaquim Ferreira and integrates 
two biostatistics, one data manager and two project managers. The group develops a 
wide range of activities that include mainly the development of databases, clinical data 
management and statistical analysis of clinical data, performance of quality control and 
de-identification activities, writing and submission of scientific papers, development of 
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research protocols and other research related documentation, and development and 
submission of scientific projects. Despite the responsibilities and functions of each 
person are well defined, there is a strong collaboration between all members of the 
group for the performance of the different activities. 
The Sub-Unidade de Bioestatística e Metodologia is engaged in several 
research projects, most of them in collaboration with other national and international 
research institutes (3). 
 
1.1.2. Unidade Regional de Farmacovigilância de Lisboa e Vale do Tejo 
The Unidade Regional de Farmacovigilância de Lisboa e Vale do Tejo 
(URFLVT, Regional Pharmacovigilance Unit of Lisbon and Tagus Valley) is one of the 
four sub-units of the Sistema Nacional de Farmacovigilância (SNF, National 
Pharmacovigilance System) (2).  
The SNF is an organized system that is focused in the monitoring of the safety 
of authorized medicinal products and in the detection of any change to their risk-benefit 
profile, in order to support decision making at various levels of the healthcare system 
(5). The URFLVT, as a structure of the SNF, shares with it its overall objectives, which 
are making more efficient the collection, treatment and study of pharmacovigilance 
data to enable the timely intervention, by responsible authorities, to ensure the quality, 
effectiveness and safety of medicines placed on the market (6).  
The URFLVT comprises the steering committee, Dr. Mário Miguel Rosa, senior 
expert at European Medicines Agency (EMA) and consultant at Autoridade Nacional do 
Medicamento e Produtos de Saúde (INFARMED, National Authority of Medicines and 
Health Products), who is responsible for defining the program of activities of the 
URFLVT and for coordinating those activities, the scientific board, consisting of 
individuals with recognized expertise in health sciences and whose function is to advise 
the steering committee on priorities, procedures and others, and the human resources 
(6). The human resources of URFLVT include one physician and two pharmaceuticals 
with training and experience in pharmacovigilance and one administrative to provide 
secretarial support with a high degree of autonomy (6). One of the pharmaceuticals 
also assumes the role of quality manager (6).  
The area of influence of URFLVT covers all healthcare units of Lisbon and 
Tagus Valley, comprising public and private healthcare units, which corresponds to a 
population of 3,659,868 inhabitants (according to a public survey from 2011) (6). The 
activities developed in this sub-unit of the UFC include reception, validation, 
classification and processing of spontaneous reports of suspected Adverse Drug 
Reactions (ADRs), including causality assessment, dissemination and promotion of the 
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reporting of suspected ADRs in the geographical area of Lisbon and Tagus Valley, 
bringing forward proposals for the realization of pharmacoepidemiology studies within 
the scope of the SNF, conducting training activities in the context of 
pharmacovigilance, preparation of relevant information to distribute to other regional 
units or international authorities and detection of safety signals in the context of 
pharmacovigilance (6). 
All the activities of URFLVT are performed in close collaboration with 
INFARMED, which is the entity responsible for ensuring the proper functioning of the 
SNF (5,6).  
 
1.1.3. Centro de Investigação Clínica 
 
The Centro de Investigação Clínica (CIC, Clinical Research Center) is the sub-
unit of the UFC that is dedicated to setting up and running clinical studies – clinical 
trials and observational studies (2). It provides a logistics structure that facilitates the 
conduction of clinical studies, ensuring the requirements for the recruitment, evaluation, 
registration of information and follow-up of research participants (2). The CIC has 
competence to perform almost all activities required by study protocols, except for 
complementary exams. The vast majority of the clinical studies conducted at CIC are 
industry sponsored. However, the CIC also supports the establishment of investigator 
driven studies.  
The CIC is dedicated to the conduction of clinical studies in neurology, mainly 
movement disorders and dementia, according to all applicable procedures, legislation 
and regulations, namely GCP, and aligning the research activity with clinical care 
delivery (2). The number of clinical studies carried out at CIC between 1999 (year in 
which the group started activities) and the first semester of 2015, according to an 
internal database, are presented in Figure 2, by neurologic disorder and distinguishing 
clinical trials from observational studies. Parkinson’s disease is the neurologic condition 
with the highest number of clinical trials conducted, with 38 trials, followed by 
Alzheimer’s disease (17 clinical trials), Multiple Sclerosis (15 clinical trials) and 
Epilepsy (13 clinical trials). Regarding observational studies, CIC has conducted, 
essentially, studies in Multiple Sclerosis.  
According to the same internal database and considering the distribution of the 
clinical trials conducted at CIC by study phase, phase III clinical trials correspond to the 
majority of clinical trials conducted, with 70 clinical trials conducted since the group has 
started functions, followed by phase II with 18 clinical trials, phase II/III with eight, 
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phase IIb with six, phase IIIb with five, phase IV with three and phase I with only one 
clinical trial. 
During my training at CIC, there were 22 clinical trials ongoing, most of all in 
Alzheimer’s disease (6), Epilepsy (4), Familial Amyloid Polyneuropathy (4), Multiple 
Sclerosis (3) and Parkinson’s disease (3), and 10 observational studies, mainly in 
Multiple Sclerosis (5) and Huntington’s disease (2). 
Figure 2. Number of clinical trials and observational studies conducted at CIC, from 1999 to the 
first semester of 2015, by neurologic disorder. Adapted from an internal database. (Amyotrophic 
Lateral Sclerosis: ALS; Familial Amyloid Polyneuropathy: FAP; Syndrome of Inappropriate 
Antidiuretic Hormone Secretion: SIAHS) 
 
The research group of CIC includes people with different backgrounds and 
expertise that work together to ensure the safety of the research participants and that 
the study protocol and the applicable regulations are consistently followed. Overall, the 
research group includes 19 investigators, mostly physicians from Hospital de Santa 
Maria (HSM) and researchers from IMM, seven study nurses, five psychologists, four 
pharmacists, two Clinical Research Coordinators (CRCs) and one laboratory 
technician. The roles and responsibilities of each member of the group are delegated 
according to their qualifications and are briefly described below: 
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 Principal Investigators (PIs) have the primary responsibility for ensuring the 
ethical conduct of the clinical trials, which includes providing adequate medical 
care to clinical trial participants and protecting their safety and well-being during 
the trials, and for ensuring protocol compliance and adherence to institutional, 
national and international regulations and guidance. The PIs also oversee all 
aspects of a clinical trial from recruitment to data collection and analysis and 
interpretation of results.  
 Sub-Investigators/ Co-Investigators may perform all or some of the PIs 
functions, which include performing study-related procedures and/or making 
important study-related decisions in compliance with the ethical and legal 
requirements and under the supervision of the PIs.  
 Clinical Research Coordinators coordinate the daily activities of the clinical 
trials, working closely with the research team to ensure that all protocol required 
procedures and visits occur according to protocol specified guidelines. The 
CRCs are also responsible for data management of the trials, which includes 
accurate and timely data entry in electronic databases and resolution of any 
data queries that may be generated. At CIC, it is also responsibility of CRCs to 
collaborate in the submission and approval process of the trials, help in the 
establishment of financial agreements and perform the overall fiscal 
management of the trials. 
 Research Nurses and Laboratory Technician are responsible for collecting 
biological samples from participants, as well as giving overall support to the rest 
of the research team. The study nurses are also responsible for performing 
some invasive procedures according to the research protocols. 
 Research Psychologists are responsible for evaluating, diagnosing and 
studying behavior and mental processes of participants through the application 
of specific clinical scales defined by the research protocols. 
 Research Pharmacists ensure procedures are followed for the control of 
medications used in clinical trials. They order, store, and dispense research 
medications, provide information to the patient about trial medications and 
oversee patient compliance. 
The CIC works in strong collaboration with the HSM in the recruitment of 
volunteers to participate in clinical studies. Besides this collaboration, over the last 
years, the CIC has also established collaborations with several other national and 
international research centres and has been involved in clinical research networks with 
a scope extending throughout the translational continuum (2).  
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1.2. Objectives 
For this curricular training I defined a set of objectives that I considered key to 
achieve a proper training in clinical trials coordination – primary objectives. The 
multidisciplinary characteristics of the UFC allowed me to develop several other 
activities related to the development of new health interventions. Therefore, I defined 
other objectives – secondary objectives – that represented specific aspects I would like 
to develop and acknowledge, in the context of clinical research. 
Primary objectives: 
 To acquire skills and qualification in coordination of clinical trials and 
observational studies; 
 To perform the daily activities of a CRC; 
 To apply and complement the previously acquired academic knowledge in a 
clinical research context; 
 To develop and improve my personal and soft skills, such as communication, 
self-confidence, critical thinking, problem solving, organization, autonomy and 
responsibility. 
 
Secondary objectives: 
 To acquire empirical knowledge on clinical trial monitoring; 
 To understand the structure, role and workflow of a regional pharmacovigilance 
unit; 
 To acquire skills in the reception, validation and processing of spontaneous 
reports of ADRs; 
 To acquire knowledge and basic skills in clinical data management and quality 
control procedures; 
 To practice medical writing skills; 
 To get a broad perspective on the multidisciplinary process of the clinical 
development of medical products and to understand how different research 
areas relate to each other. 
 
 
1.3. State of the Art of the Pharmaceutical R&D Process and the 
R&D in Neurology 
Over the past few years, pharmaceutical and biopharmaceutical companies 
have played a major role as drivers of significant medical innovation (7–9). The 
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research-based pharmaceutical industry applies the most up-to-date technology and 
scientific knowledge to discover, develop and bring to clinical use new medicinal 
products that significantly increase patient survival rates and life expectancy, delay 
disease progression and improve quality of life (7–9).  
 
1.3.1. The Pharmaceutical R&D Process: Overview, Challenges and Trends 
  
Discovering and developing new drugs is a complex and long-term process that 
consists of several stages and involves various players (8,10). The pharmaceutical 
R&D (Figure 3) begins with drug discovery followed by preclinical drug development, 
which includes in vitro and in vivo tests to assess the pharmacokinetic and toxicological 
properties of compounds, in order to obtain initial proof of safety and effectiveness 
(8,10). Compounds that demonstrate attractive therapeutic, pharmacological and 
toxicity properties, usually 5 or fewer from an original pool that may total 10,000, are 
subject to three stages of clinical trials (Phase I, II and III) to test their safety and 
efficacy in humans (8,10). After extensive testing and study, a candidate drug is 
submitted for regulatory approval (8,10). If approved, post-marketing research and 
monitoring ensues to gather information on the drug's efficacy in specific patient 
subgroups and any side effects associated with long-term use (8,10).  
 
 
 
Figure 3. The current pharmaceutical R&D process. Adapted from (10). 
 
The task of discovering and developing safe and effective drugs is a risky 
business (11). Recent studies show that the R&D process is a lengthy process, with an 
average of 7.2 years to bring a medicine from the beginning of the clinical phase to 
regulatory approval (11). Also, the likelihood that a compound entering clinical testing 
will reach the marketplace is estimated to be less than 16% (11). These two factors, 
long development times and low success rates, along with the high volume of 
resources required, are translated into very high drug development costs, which were 
recently estimated to be $2.6 billion (8,12). Therefore, it is easy to understand that the 
R&D process, as described, is unsustainable.  
The recognition of this unsustainability has resulted in the proposal of a new 
model, with the purpose of improving the R&D productivity (13). The new R&D model 
aims to establish a drug development process that generates an iterative knowledge on 
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the relationship between the therapeutic approach and disease pathophysiology, 
allowing for a continuous improvement of the medicine throughout development (13). 
This approach is focused in the obtainment of a holistic understanding of the 
pathophysiology of the disease before starting the clinical phase of the development 
and in the reduction of the uncertainty on the safety and efficacy profile of the medicine 
before the expensive later development stages (Phase II and Phase III), through the 
establishment of proof-of-concept trials (13). These trials allow to determine whether a 
treatment is likely to be efficacious for a given indication and thus whether it is worth 
investing the financial resources, time and participant exposure necessary for a 
confirmatory trial of that intervention (13).  
This paradigm shift will be facilitated by the use of adaptive clinical trial designs, 
which can make the R&D process more flexible and efficient, reducing development 
costs and time and increasing the probability of success (13). Another important tool in 
this new R&D model is the use of biomarkers (13,14). Indeed, biomarkers can be used 
to stratify patient populations with specific disease subtypes to better define the study 
population of each new medicine and, thus, reducing the number and size of clinical 
trials required to get regulatory approval (13,14). Moreover, the use of surrogate 
biomarkers, often considered as replacement for clinically meaningful endpoints, may 
dramatically shorten the time necessary for critical go/no go decisions in clinical 
development, as clinically meaningful endpoints may take years to evaluate (13,14).  
Like biomarkers, new technologies will be crucial for this new R&D process 
(13,14). The technological advances will allow pharmaceutical companies to improve 
the ability to predict a new drug’s efficacy and safety in new patient populations 
(13,14). New technologies will also create the possibility of pharmaceutical companies 
to monitor patients on a real-time basis and outside the clinical setting, in order to gain 
a more deep understanding on the course of diseases, and will increase the capability 
of companies to align and integrate internal information with public data sources, 
resulting in a greater amount of information available (13,14).  
 
1.3.2. The R&D Process in Neurological Diseases 
In developing new drugs for neurological diseases, the pharmaceutical industry 
faces several challenges related to both disease state and conducting clinical trials 
(15). 
Currently, and despite the great advances in scientific knowledge over the last 
years, there is still a lack of information and understanding on the mechanisms of 
neurological diseases, which difficults the identification and/or development of novel 
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mechanisms of action for drugs and the evaluation of their effects (15). Neurological 
diseases also lack predictive animal models, increasing the uncertainty throughout the 
R&D process, and precise measures of efficacy and safety, which compromises the 
assessment of the real effect of drugs (15).  
With regard to the conduction of clinical trials, neurological conditions are 
characterized by an increased difficulty in recruiting and retaining eligible patients (15). 
On one hand, neurological conditions are associated with cognitive and physical 
impairment, making it difficult to perform the required procedures, including the 
obtainment of informed consent (15). On the other hand, clinical trials on neurological 
indications have very restrictive inclusion criteria and require longer time periods to 
demonstrate efficacy, due to the slowly progression of diseases (15).  
As a result, neurological disorders have longer clinical development timelines 
compared to the majority of therapeutic classes (16). In fact, the average time required 
to perform phase II and III clinical trials increases from 6.1 years in the majority of 
therapeutic classes to 8.1 years in neurological diseases (16). Additionally, the average 
time to get regulatory approval increases in neurological disorders – approximately 1.9 
years compared with an average of 1.2 years for the majority of therapeutic classes 
(16). Therefore, without considering the time for discovering and perform preclinical 
tests, it takes around 9 years to bring a new medicine for neurological diseases to the 
market (11). Besides the longer clinical development timelines, the chance of 
compounds for neurological diseases succeeding in phase III clinical trials decrease 
from 66% to 46% (16). Also, only 8% of the drugs that initiate the development phase 
receive regulatory approval (11,16).  
The comparison between the metrics in the R&D process in neurological 
disorders and non-neurological disorders is represented in Figure 4.  
 
 
Figure 4. Comparison between R&D metrics in neurological disorders and non-neurological 
disorders. Adapted from (11,16). 
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Despite the challenges of developing drugs for neurological disorders, the 
rewards of bringing neuropharmacologic agents to the market can overcome the risks 
(16). Neurological disorders significantly outnumber diseases in other therapeutic 
areas, with more than 600 known conditions affecting the nervous system and with a 
growing incidence as a result of the aging of the population, and are associated with 
higher treatment and loss of productivity costs (16). These factors have contributed to 
encourage the pharmaceutical industry to keep investing in neurological disorders and 
develop new medicines that work more precisely and more effectively (16). According 
to a report released by the Pharmaceutical Research and Manufacturers of America, 
biopharmaceutical research companies are currently developing 420 medicines for 
patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, 
multiple sclerosis and Parkinson’s disease (17).  
 
1.3.3. Trends and Directions in CNS Drug Development 
Pharmaceutical companies are shifting the traditional R&D process for CNS 
disorders to a process with a higher focus on risk-lowering activities, such as cost-
diluting partnerships, increased in licensing and Mergers & Acquisitions activities, and 
a heavier focus on preventing failures at earlier stages of the development, through 
improved in silico modelling (16).  
Over the last years, the vast majority of the neuropharmaceutical development 
has been conducted on a partnership or collaboration basis, with CNS licensing deals 
being responsible for 14% of all pharma licensing deals in 2012 and for 15% in the first 
half of 2013 (16). Also, the pharmaceutical industry has been focusing in settle 
cooperation and collaboration agreements with academic experts to promote basic 
research in CNS disorders (16). In 2010, the UCB-Pharma established a research 
alliance with the Harvard University where the company provided up to $6 million, over 
two years, to fund innovative research projects with potential for the development of 
new therapeutic modalities for CNS conditions, led by Harvard scientists (18). More 
recently, Teva Pharmaceutical Industries LTD invested $15 million into more than 50 
CNS research projects at universities across Israel seeking for next-generation 
treatments for its pipeline (16). 
Like pharmaceutical industry, regulatory authorities are also supporting 
collaborative research projects and building networks of industrial and academic 
experts in order to foster the development of new innovative drugs for CNS indications 
(19).  
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The Innovative Medicines Initiative (IMI) is a public-private initiative of the 
European Commission (EC) and the European Federation of Pharmaceutical Industries 
and Associations that aims to improve health by speeding up the development of and 
patient access to innovative medicines, focusing on areas where there is an unmet 
medical or social need (19). One of the main focus of IMI was the improvement of drug 
R&D in CNS disorders through implementation and support of specific projects (19).   
In its first phase, from 2008 to 2013, for CNS disorders, this initiative 
implemented and funded projects that addressed the identification and validation of 
pre-symptomatic and surrogate markers for disease progression and the development 
of model systems that were more predictive of the clinical efficacy of new drugs, and 
projects that aimed to gain a better understanding of disease mechanisms at systems 
level (20).  
For its second phase, period between 2014 and 2020, IMI is intended to 
support projects aimed at identifying and validating novel targets for prevention and 
slowing of disease, identifying/developing biomarkers, and developing non-invasive 
methodologies for assessing disease progression and drug efficacy and safety (21). 
Other projects supported in this second phase are those that adopt innovative clinical 
trial paradigms, develop methodologies to demonstrate impact of disease and resultant 
benefit of treatments, and develop better formulations and delivery methods to support 
improved adherence to medicines (21).  
Besides IMI, there are several other initiatives, such as the European Union 
Joint Programme – Neurodegenerative Disease Research and the Network of Centres 
of Excellence in Neurodegeneration, that aim to increase coordinated investment and 
to build collaborative research activity in neurodegenerative diseases to accelerate the 
scientific knowledge and the development of new tools for identifying and treating 
neurodegenerative diseases, as well as to improve social assistance for patients 
(22,23). 
 
1.3.4. Clinical Trials  
 
Clinical trials are research studies intended to answer scientific questions and 
find better ways to treat or prevent diseases (24). According to the International 
Conference on Harmonization (ICH) GCP E6 guidance, a clinical trial is “any 
investigation in human subjects intended to discover or verify the clinical, 
pharmacological and/or other pharmacodynamic effects of an investigational 
product(s), and/or to identify any adverse reactions to an investigational product(s), 
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and/or to study absorption, distribution, metabolism, and excretion of an investigational 
product(s) with the object of ascertaining its safety and/or efficacy” (25).  
Although the definition of clinical trial had been associated with the study of 
drugs, currently it is broadly used to include other forms of intervention besides drugs 
such as surgical procedures, radiological procedures, medical devices, behavioural 
treatments, process-of-care changes, preventive care, etc (24,26).   
 
1.3.4.1. Types of Clinical Trials 
Assessing the efficacy and safety of a new intervention often requires several 
different clinical trials (27). Typically, the testing in humans is described as consisting of 
four temporal phases (Phase I-IV) (27). However, one type of trial may occur in more 
than one phase and a classification based on the objective of the trial is more adequate 
(27). 
Each phase of clinical testing has specific and differing requirements for patient 
population, objectives, inclusion/exclusion criteria, design features, and expected 
outcomes (28). Ideally, clinical testing is carried out in a logical, step-wise procedure 
with results from prior clinical trials being used to support and plan trials performed 
later in the development process (27). The clinical testing progress from trials designed 
to evaluate short-term safety and tolerability (Phase I), to trials aimed at defining dose-
response relationships (Phase II) and at determining the efficacy and safety with the 
dose(s) of interest (Phase III) (28). 
  Phase I (Human pharmacology studies) 
Phase I studies are the initial phase of testing in humans and are primarily 
designed to assess the tolerability and safety of the drug (27). Usually, phase I studies 
use dose escalation designs to determine the maximum tolerated dose (28). 
Additionally, data on pharmacokinetics and pharmacodynamics and drug metabolism, 
interactions and activity are collected (27). These type of studies include about 20 to 
100 healthy volunteers without confounding diseases or concurrent medications (28). 
However, when there are toxicity limitations, phase I studies are performed in 
volunteers with the disease or condition of interest (27,28). 
This phase of testing takes approximately 1.5 years to complete (28).  
 Phase II (Therapeutic exploratory studies) 
Phase II studies are performed with the intent of exploring use in the target 
indication in patients with the condition or disease of interest (27). Additionally, phase II 
studies also help to determine the common short-term side effects and risks associated 
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with the drug (27). These studies are well controlled and closely monitored and use a 
relatively homogeneous population, with very tight inclusion and exclusion criteria, of 
several hundred (100 to 300) patients (28). The first clinical trials of this phase of 
testing may have a variety of designs (27). However the subsequent trials are 
randomized, controlled and blinded (27). 
A major focus of this phase of testing is to estimate dosage and/or dosage 
scheme for subsequent trials and provide basis to define the design, endpoints and 
methods for confirmatory studies (28). 
Usually, phase II studies take around 2 years to complete (28).   
 Phase III (Therapeutic confirmatory studies) 
Phase III studies aim to confirm the efficacy of the drug in the target indication 
and establish drug safety profile and dose–response relationship (27). The information 
gathered in these studies constitutes the basis for assessing the benefit-risk 
relationship of the drug, in order to get regulatory approval for marketing (27,28). The 
typical study design used in phase III trials is randomized and placebo-controlled, but 
an active comparator control group can be considered (28). The patient population of 
phase III studies is more heterogeneous than that studied in phase II and, usually, 
includes 1,000-3,000 patients distributed over many sites (28). 
Studies in phase III usually require about 2.5 years to complete (28). However, 
in some cases, this timeline can be extended to 5 years (28).  
 Phase IV (Therapeutic use studies) 
Phase IV studies are conducted after a drug has been approved for marketing 
and include only studies performed in the approved indication(s) (27). These studies 
aim to monitor a drug's long-term safety and efficacy, in order to refine the 
understanding on the benefit–risk relationship and impact on a patient's quality of life, 
to identify less common adverse reactions and refine dosing recommendations (27). 
Over the past few years, these type of studies have also been used to determine the 
cost-effectiveness of a drug over other drugs already on the market or new ones (28).  
Studies in phase IV have more simple study designs and are often very large 
(28). 
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1.3.4.2. Regulatory Framework 
Considering the ethical and safety concerns regarding study participants, the 
importance of the information gathered and the multiplicity of stakeholders involved, it 
is easy to understand that clinical trials are a highly regulated activity (29).  
Over the last years, several directives, regulations, guidance documents and 
ethical standards have been published to protect the rights and integrity of patients and 
study volunteers and to guarantee the high quality of the data produced/collected (29). 
Despite the existing amount of legislation and guidance documents concerning the 
conduction of clinical trials, the most important ones are the following: 
 Declaration of Helsinki, which specifies a series of ethical principles for medical 
research involving human subjects, including research on identifiable human 
material and data, in order to protect research participants (30). Although it has 
no legal status, it is recognized, on a global scale, as the code of conduct of 
medical research on humans and is referenced in nearly all clinical trial 
protocols submitted to ethics committees; 
 ICH GCP E6 guidance, which outlines a set of principles that aim to ensure the 
rights, safety and well-being of research subjects, and the high quality and 
credibility of the clinical data obtained, by defining, in detail, the responsibilities 
and obligations of all parties engaged and by defining standards for designing 
and conducting research and recording and reporting data (25); 
 Directive 2001/20/EC of the European Parliament and of the Council of 4th April 
2001, which is also known as the Clinical Trial Directive and aims to harmonize 
the research activity in the European Community by providing a framework that 
sets out how clinical trials must be conducted to ensure the protection of the 
trial participants and the overall quality of the trial (31). Initially, this directive 
was transposed into the Portuguese national law by Decree-Law 46/2004 of 
August 19th. More recently, this Decree-Law was repealed by Decree-Law 
21/2014 of April 16th (32); 
 Commission Directive 2005/28/EC of 8 April 2005, or the GCP Directive, which 
complements the Directive 2001/20/EC by setting out the principles and 
guidelines of GCP applicable to clinical trials and the requirements for 
authorization of the manufacturing or importation of investigation medicinal 
products (33). In the Portuguese legislation, the principles set out in this 
directive are specified in Decree-Law 102/2007 of April 2nd (34); 
 Directive 95/46/EC of the European Parliament and of the Council of 24 
October 1995,  also known as the Data Protection Directive, which sets up a 
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regulatory framework that ensures the protection for the privacy of individuals 
by defining limits on the collection and use of personal data (35). This directive 
was transposed to national law by Law No 67/98 and by Deliberation 
nº333/2007 (36,37); 
 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 
16 April 2014, which repeals the Directive 2001/20/EC and aims to make 
clinical trials simpler to set up, mainly through the establishment of a centralized 
system for approving clinical trials, and more transparent in reporting their 
results, including negative findings (38). This Regulation also intends to 
eliminate the disparity adopted by Member States in transposing the Directive 
2001/20/EC (38). Although it has entered into force on 16 June 2014, it will only 
apply starting from 28 May 2016 (39). 
 
1.3.4.3. Clinical Trials in Portugal 
The number of clinical trials submitted to INFARMED between 2006 and 2012 
show a decrease of 26%, from 160 to 118 trials (Figure 5), making Portugal one of the 
countries of the Western Europe with the lowest rate of clinical trials per million 
inhabitants (40). In the last three years (2012, 2013 and 2014), there seems to be a 
tendency towards the stabilization of the number of clinical trials submitted to 
INFARMED (Figure 5) (41).  
 
 
Figure 5. Number of clinical trials submitted to and approved by INFARMED and sponsored by 
the pharmaceutical industry and by academic institutions, from 2006 to 2014, in Portugal. 
Adapted from (41). 
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According to a study released on 2013 on the clinical trials activity in Portugal, 
the large majority of the clinical trials conducted were sponsored by the pharmaceutical 
industry (40). Data from 2012 show that 112 of the 118 trials submitted to INFARMED 
were sponsored by pharmaceutical companies, with only 6 trials being submitted by 
academic institutions (Figure 5) (41), which represents a very low expression, 
especially considering other Western European countries where academic trials 
represent about a quarter of the total number of trials conducted (40). This tendency is 
supported by the latest statistics on the sponsorship of the clinical trials submitted to 
INFARMED (Figure 5) (41). Also, phase III and IV clinical trials were responsible for 
80% of all trials conducted in Portugal in the last years, with phase III trials alone being 
responsible for 68% of the trials approved in 2012 (40). In what concerns phase I 
clinical trials, these had almost no representation, with only 8 trials approved between 
2009 and 2012 and with only 10 trials submitted in 2013 (41).  
Regarding the number of patients enrolled in clinical trials, Portugal had also 
been far below the other countries of the European Economic Area (40). Data from a 
report released by the EMA on the patient recruitment and geographical location of 
investigator sites of clinical trials submitted to the Agency, between 2005 and 2011, 
Portugal included an average of 23 patients per trial, a small number compared to 
countries like Hungary and Czech Republic (82 and 107 patients, respectively), which 
have a population comparable to that of Portugal (42). 
The reduced number of clinical trials conducted in Portugal over the last years 
is revealing of a progressive loss of competitiveness of the country (40). The lack of 
interest from sponsors to conduct clinical trials in Portugal is harmful to the country and 
its economy, as it prevents the access of the population to new and innovative 
therapies, the adoption of best practices in monitoring of patients, the improvement of 
supportive care and cost savings with healthcare (40). 
The recognition of this worrying reality resulted in the definition of a new 
strategy, by the Ministry of Health, to promote clinical research and to increase 
competitiveness and transparency in this sector (43). On April 16th of 2014, the Law 
21/2014 was approved (32). This Law represents a change in the legislation in force by 
establishing a more comprehensive and harmonized legal framework, covering not only 
clinical trials with medicinal products but also studies with medical devices, cosmetics, 
food supplements and all kind of observational studies, and by defining new timelines 
for approval of clinical trials (32), which have been identified as one of the most limiting 
factors of this activity in Portugal (40). Indeed, this Law establishes more competitive 
timelines with a considerable reduction in the time provided to all parties involved in the 
approval process to take a position on the conduction of the trial (32).  
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The Law 21/2014 also establishes the creation of an electronic platform for 
registration of clinical trials, the Registo Nacional de Estudos Clínicos (National Clinical 
Trial Register) (32). This platform aims to promote the interaction between the different 
stakeholders in clinical research, facilitating and encouraging the development of high 
quality research, and the dissemination of the clinical research activity (32). 
Furthermore, the Law defines the creation of the Rede Nacional de Comissões de 
Ética para a Saúde (National Ethics Committees Network) promoting harmonization on 
the assessment of clinical trial applications and the mutual recognition between 
national ethics committees (32).  
Besides the approval of the new Law, two other initiatives are under 
development by the Ministry of Health, in order to increase the clinical trials activity in 
Portugal (43). The first one is the revision of the criteria for purposes of career 
progression, in a first stage, for physicians who assume the role of investigators and, in 
a later stage, for other professionals involved in clinical research (43). The other 
initiative is the establishment of a research fund, sustained by the Ministry, which aims 
to ensure suitable conditions for projects by initiative of investigators (43).  
 
1.3.4.4. Clinical Trials in Neurology 
Clinical trials involving CNS disorders are among the most difficult ones to set 
up and run (16). As mentioned above, clinical trials in neurology are associated with 
subject recruitment and retention problems (16). In fact, the available diagnosis 
techniques for neurologic disorders are very poor and, in the vast majority, outdated 
considering the recent technological advances, resulting in delayed diagnosis (16). 
Therefore, patients often fail to meet inclusion criteria due to the advanced stage of 
diseases (16).  
The recruitment of patients for clinical trials is also difficult due to the restrictive 
inclusion criteria, the informed-consent process and the assessment procedures (15). 
Neurological diseases are associated with cognitive impairment, compromising the 
ability to make decisions such as participation in clinical trials, which difficulties the 
obtainment of informed consent from patients, and the ability to comply with the study 
procedures and with the study medication (15). Along with the common impaired 
cognitive abilities, the physical immobility of patients with CNS disorders is also a major 
hurdle in clinical trials, mainly in those that require long periods of time (15).  
The assessment of the effect and safety of drugs for CNS indications in clinical 
trials often requires frequent hospital visits and the use of exhaustive evaluation 
processes/tools, which can restrict patient compliance or make subjects to withdraw 
consent to participate in the trial (15). This difficulty in retaining eligible patients along 
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with the difficulty in recruiting patients can result in small sample sizes, compromising 
the assessment of the effect of the drug (15).  
Besides the frequent small sample sizes of CNS trials, the difficulty in 
determining the effect of CNS drugs is further exacerbated by relatively poor diagnosis 
techniques, which do not allow the distinction between different stages of disease (16). 
It is usual to have a cohort of patients in a clinical trial among which disease 
progression would vary drastically, making it difficult to assessing the effect of the drug 
(16). Another hindrance in determining the effect of the experimental drug in CNS trials 
is the placebo effect (16). Currently, the vast majority of clinical assessments is based 
in neuropsychological scales, which can be influenced by confounding cognitive, mood 
or personality changes of patients caused by the belief that they are being treated (16).  
Although neurological conditions represent a substantial clinical challenge, 
between 2005 and 2010, the number of clinical trials registered in the ClinicalTrials.gov 
database in CNS disorders was the highest among the non-oncology group of 
therapeutic areas, with 7,751 trials (44). In December 2011, there were 603 phase I-III 
clinical trials in neurologic diseases filed with the Food and Drug Administration, with a 
higher number of earlier-phase trials (256 phase I, 273 phase II and 74 phase III trials) 
(45). Nevertheless, neurology was the third most common therapeutic area in Phase III 
clinical trials, after cancer and infections (45).  
Considering the number of clinical trials submitted to INFARMED between 2006 
and 2014, CNS disorders accounted for one of the therapeutic areas with the highest 
number of clinical trials submitted (Figure 6) (41).  
 
Figure 6. Number of clinical trials submitted to INFARMED from 2006 to 2014, by therapeutic 
area. Adapted from (41). 
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 The numbers presented corroborate that neurological diseases have been a 
therapeutic area greatly focused on by pharmaceutical companies (44). 
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2. On-the-Job Training 
During my curricular training, I had the opportunity of interacting and 
collaborating with different research areas in the host institution. In this chapter, I 
present a detailed description of all the activities performed during this 10-month 
period. The training received is divided into generic training and specific training, 
according to the level of qualification acquired. The generic training corresponds to the 
activities developed in the context of data management, pharmacovigilance and 
medical writing and the specific training describes the activities developed as trainee in 
clinical trials coordination. 
The first two months of the training were carried out in the Sub-Unidade de 
Bioestatística e Metodologia where I was able to participate in several activities, such 
as management of clinical databases for statistical analysis and in the development of 
documents in the context of data management activities, mainly quality control of 
clinical data.  
After my experience in the Sub-Unidade de Bioestatística e Metodologia, I had 
the opportunity of collaborating with the URFLVT. During this collaboration I was able 
to acquire knowledge and skills in the area of pharmacovigilance and to gain 
qualification for the daily activities of this unit, mainly for the reception, validation and 
processing of spontaneous reports of ADRs. 
For the last six months of the training I went to the CIC where I learned to 
perform the daily activities of a CRC, from the preparation and conduction of study 
visits to the completion of Case Report Forms (CRFs) and resolution of queries, 
including all the logistical aspects related to the conduction of clinical trials.  
Besides the clinical trials coordination, data management and 
pharmacovigilance activities performed, I also had the opportunity to participate in a 
series of parallel projects in the host institution, mainly writing of scientific papers. 
 
2.1. Generic Training 
During my curricular training I had the opportunity of collaborating and 
participate in several activities besides the coordination of clinical trials. The purpose of 
the developed activities was to get a broad perspective on the multidisciplinary process 
of the clinical development of medical products and health research activities, as well 
as to understand how different research areas relate to each other. These activities are 
schematically represented in Figure 7 and are fully described in the following pages.    
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Database management 
GCP course
Processing of notifications of ADRs
Other Activities
Medical writing
Training on ongoing clinical trials
 
Figure 7. Timeline of the main activities developed in the generic training. 
2.1.1. Training on the Ongoing Studies and Organization of the CIC 
During my first week of the training, I went to the CIC where I received training 
on the ongoing clinical trials and on the research team of the sub-unit. The main 
purpose of this training introduction was to prepare me to start the specific activities of 
clinical trials coordination. 
2.1.1.1. Ongoing Clinical Trials 
 
The study protocol describes how a clinical trial will be conducted and ensures 
the safety of the trial participants and the integrity of the data collected (25). The 
training on the study protocol is given to the research team in the investigators meeting 
and in the site initiation visit and ensures protocol compliance. 
When I first arrived at CIC, to obtain a knowledge on the ongoing trials, I did a 
comprehensive reading of the study protocols and complemented the knowledge on 
them by clarifying the doubts with the CRCs of the CIC. After that, I was able to actively 
participate on the clinical trials. 
2.1.1.2. The Research Team 
The clinical research activity requires teams dedicated to clinical research and 
qualified according to the standards of GCP and to the applicable legal and quality 
requirements. The research team, comprises any person delegated by the research 
team leader to have operational charge of any specific procedure of the trial.  
During my first week in CIC I was introduced to all members of the research 
team of the sub-unit and instructed regarding the clinical trials and the specific roles 
delegated to each member. This was important to facilitate the management of the 
different studies.  
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2.1.2. Data Management Activities 
My curricular training in the Sub-Unidade de Bioestatística e Metodologia was 
focused on quality control activities and organization of databases of clinical data for 
statistical analysis. The purpose of this part of the training was to acquire basic 
knowledge and skills in clinical data management. 
2.1.2.1. Quality Control Plan 
Within the scope of quality control activities, the Sub-Unidade de Bioestatística 
e Metodologia is responsible for editing, cleaning, verifying, cross-checking and 
validating data collected in clinical studies, in order to ensure their reliability and 
credibility.  
During my training in this research sub-unit, I was challenged to collaborate in 
the development of a quality control plan where I had to identify the methodologies to 
be used for checking data completeness, integrity and consistency, and for detecting 
double data entry, missing values, out-of-range values, anomalous values and errors, 
in order to validate data for statistical analysis. This activity was carried out within the 
scope of the Enroll-HD study, a worldwide observational study for Huntington’s disease 
that aims to increase the knowledge on the biology of the disease to enable clinical 
research for improving clinical care of people with Huntington’s disease, through 
collection of clinical data and biological samples (46). 
 
2.1.2.2. Database Management  
Usually, the data collected in clinical studies requires to first be processed so 
that the statistical analysis can be made. In this context, during my training in the Sub-
Unidade de Bioestatística e Metodologia, I had to organize two different databases.   
One of the databases was intended to gather data collected in the project 
Sense-Park, a European funded initiative that aims to develop a series of technical 
devices that allow the continuous assessment of motor and non-motor symptoms 
(sleep, tremor, rigidity, stiffness, walking, gait) for an objective and precise analysis and 
measurement of Parkinson’s disease (47). For this purpose, I converted the original 
records on the clinical domains (motor and non-motor symptoms) collected with the 
devices into means and medians and entered the values into a database, in a way that 
data could be directly used by statistical software.  
The other database was intended to organize data on ADRs for which the 
suspected drugs were thrombolytics, anticoagulants and/or antiplatelet aggregation 
drugs, for statistical analysis. In this database I had to disaggregate some variables 
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and to calculate others, such as body mass index. This database was developed within 
the scope of a personal project of an investigator of the UFC.  
 
2.1.2.3. Other Activities 
Besides the quality control and database management activities, I was able to 
assist in several other secondary activities. These included search the internet for best 
practices for data cut release and for methods for de-identification of protected health 
information, both within the scope of the Enroll-HD study, adaptation of a manuscript to 
the formatting requirements of the Journal of Parkinson's Disease, and collaboration in 
the submission of a project to a research grant sponsored by the Santa Casa da 
Misericórdia de Lisboa (Holy House of Mercy of Lisbon). 
2.1.3. Pharmacovigilance Activities 
My curricular training in the URFLVT was divided into two main components: 1) 
acquisition of basic knowledge on pharmacovigilance and its regulatory framework, 
presentation of the SNF and of the URFLVT, and understanding of the URFLVT quality 
management system and workflow, and 2) reception, validation and processing of 
spontaneous reports of ADRs. The main objective of this part of the training was to 
gain knowledge on the structure of the unit, its mission, requirements, vision and 
activities, and to gain qualification to perform the daily activities of a regional 
pharmacovigilance unit.  
2.1.3.1. Regulatory Framework 
Pharmacovigilance is governed by several regulations, directives, guidelines, 
and standards that ensure the accurate conduction of pharmacovigilance activities. In 
the first week of my curricular training at URFLVT, I was invited to read the main 
pharmacovigilance regulatory documents, in order to better understand the specific 
requirements of the URFLVT, and then, to properly carry out the training activities. 
These documents included: 
 Directive 2010/84/EU of the European Parliament and of the Council of 15 
December 2010 and Regulation (EU) No 1235/2010 of the European 
Parliament and of the Council of 15 December 2010, which lay down the 
community procedures for the pharmacovigilance of medicinal products for 
human use within the EU (48,49); 
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 Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012, 
which complements the 2010 pharmacovigilance legislation by providing more 
technical details that have to be observed by marketing authorization holders, 
national competent authorities and EMA in the daily practice of applying the 
new legislation (50); 
 Decree-Law 20/2013 of 14 February 2013, which transposes into national law 
the Directive 2010/84/EU (51); 
 Directive 2012/26/EU of the European Parliament and of the Council of 25 
October 2012, which clarifies and strengthens the procedures used to resolve 
issues such as concerns over the safety or benefit-risk balance of a medicine or 
a class of medicines (52); 
 Regulation (EU) No 1027/2012 of the European Parliament and of the Council 
of 25 October 2012, which defines a list of medicinal products that are subject 
to additional monitoring (53); 
 Good Pharmacovigilance Practices – Module VI, which presents a set of 
measures drawn up to facilitate the management and reporting of adverse 
reactions to medicinal products (54). 
2.1.3.2. Quality Manual and Procedures 
Since August 2013, the URFLVT has implemented a quality management 
system, in accordance with the European version of the International Organization for 
Standardization 9001:2008, to consistently accomplish its objectives and to ensure 
compliance with all regulatory requirements applicable to its activity. One of the key 
components of the URFLVT quality management system is the quality manual that 
contains the quality policy and goals of the unit, as well as a detailed description of its 
quality control system, which includes staff roles, procedures and interactions between 
procedures, systems and any other resources required to perform specific activities.  
Before I start performing any activity, I read the URFLVT quality manual, mainly 
to become aware of the specific steps to follow to carry out the different 
pharmacovigilance activities – working instructions. Considering the activities to be 
undertaken during the training, I focused on the working instructions related to the 
reception and validation of ADRs, preparation of the initial notification report, request 
for additional information on notifications and preparation of the follow-up report.  
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2.1.3.3. Pharmacovigilance Course 
During my first week in the URFLVT, I had the opportunity to attend an 
intensive course of 16 hours on pharmacovigilance, organized by the URFLVT. The 
course provided an overview on the mechanisms of ADRs, methods for drug safety 
monitoring, risk-benefit assessment of drugs, causality assessment of ADRs and 
pharmacoepidemiology studies. The course also gave a brief insight on the most 
common ADRs for the different systems of the human body, with a description of the 
mechanisms that are involved and identification of the most likely causative drugs.  
2.1.3.4. Reception, Validation and Processing of Spontaneous Reports of 
ADRs 
The main activity performed during my curricular training in the URFLVT was 
the reception, validation and processing of spontaneous reports of ADRs. A 
spontaneous report is an unsolicited communication by healthcare professionals or 
consumers that describes one or more ADRs in a patient who was given one or more 
medicinal products and that does not derive from a study or any organized data 
collection scheme (54). Spontaneous reports of ADRs are the main source of data on 
the safety of medicines used by the SNF (55). The major value of spontaneous report 
systems lies in the early detection of possible drug safety problems that have not yet 
been identified (56). Also, spontaneous reports allow for large scale and continuous 
monitoring of the safety of drugs and the identification of risk groups and serious and/or 
rare adverse effects (56).  
During the second half of 2014, which includes the period I was in the URFLVT, 
422 spontaneous reports of ADRs were received, validated and processed. The 
reception, validation and processing of spontaneous reports of ADRs in the URFLVT is 
done according to specific written procedures. During my training, I received, validated 
and processed spontaneous reports of ADRs, always under the close supervision of 
the two pharmaceuticals of the unit. Following, I present a description of the process 
used to receive, validate and process spontaneous reports of ADRs. 
 
 Reception and Validation of Spontaneous Reports of ADRs 
When a spontaneous report of ADR was received in the URFLVT, the first step 
was to validate the report, which consisted in verifying that: (1) the notification 
belonged to the area of activity of the URFLVT; (2) the report did not correspond to a 
duplicate of a previously received one; (3) the suspected drug was actually a drug; and 
(4) the four minimum criteria for acceptance of a report (one or more identifiable 
reporter(s), one single identifiable patient characterized by initials, patient identification 
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number, date of birth, age, age group or gender, one or more suspected medicinal 
product(s) and one or more suspected ADR(s)) were present. If all criteria were met, I 
signed and dated the report with the date of the reception and assigned a code number 
to indicate that the report was validated. When a report did not meet the minimum 
criteria, especially if it corresponded to a serious and/or unexpected ADR, I made 
attempts to get all necessary information from the reporter or other available sources. 
 
 Processing of Spontaneous Reports of ADRs 
The processing of spontaneous reports of ADRs was made within a maximum 
of 7 days following their reception and validation. In order to avoid deviations, once the 
report was considered valid, I set a time limit in the calendar for completing the 
processing of the report. 
After validation, I classified the ADR as described/non-described, according to 
the information in the summary of product characteristics, and, if not provided by the 
reporter, as serious/non-serious, if the ADR was present in the Important Medical 
Event Terms list and/or in the Council for International Organizations of Medical 
Sciences list. These two documents contain a set of ADRs that must always be 
considered as serious. Also, if the reporter classified the ADR as non-serious, I made a 
search in the mentioned lists to ensure that the ADR was not required to be considered 
as serious.  
Besides classifying the ADR, I had to code it to terms in the Medical Dictionary 
for Regulatory Activities (MedDRA). The MedDRA is a standardized set of medical 
terminology used for registration, documentation and safety monitoring of medical 
products, that was developed to facilitate sharing of regulatory information (57). After 
classifying and coding the ADR, I introduced the information present in the report on a 
platform – Portal de Reações Adversas a Medicamentos (Portal RAM, Portal of 
Adverse Drug Reactions) – , managed by INFARMED, that enables the collection of 
information on suspected ADRs occurred in Portugal. 
After entering the data of the spontaneous report in Portal RAM, I contacted the 
reporter to obtain additional information relevant for the scientific evaluation of the 
case. This information, together with the data of the report, was then used to write a 
narrative of the case, in which I described the patient characteristics, therapy details, 
medical history, diagnosis, ADR and its outcomes, relevant laboratory evidence and 
any other relevant information. This narrative was also introduced in Portal RAM. 
The information introduced in Portal RAM was always checked by one of the 
two pharmaceuticals of the unit to verify that the ADR was correctly classified and 
coded and the information was correctly introduced.  
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The last step of the processing of spontaneous reports was the causality 
assessment, which defined the probable causal relationship between the suspected 
medicinal product and the ADR. The causality assessment was done by the steering 
committee, within 30 days after the validation of the spontaneous report. Once the 
assessment was done, I prepared the causality letter identifying the causal relationship 
attributed to the case to send to the reporter and wrote the causality report and 
attached it in Portal RAM. 
When the information of the spontaneous report was incomplete, I made a 
follow-up contact with the reporter, usually one month later, to obtain new information 
that has arisen and did a follow-up report, which complemented the narrative of the 
case.  
All the information introduced in the Portal RAM was sent to the SNF database 
SVIG (Sistema de VIGilância, Vigilance System). This database gathers all 
spontaneous reports from the different regional pharmacovigilance units. 
 
2.1.4. Medical Writing Activities 
During my training in the Sub-Unidade de Bioestatística e Metodologia, I had 
the opportunity to collaborate in other projects outside the scope of activities of the sub-
unit, most of them related to systematic reviews and meta-analysis on cardiovascular 
topics. 
2.1.4.1. The impact of systematic reviews with meta-analysis on the 
European Society of Cardiology’s guidelines 
This was a study carried out to evaluate different methodologies used for 
identification of systematic reviews and/or meta-analysis cited in the 2001, 2006, 2010 
and 2012 American College of Cardiology/American Heart Association/European 
Society of Cardiology guidelines for the management of patients with atrial fibrillation. 
The identification of the systematic reviews and meta-analysis was performed 
using four different methods: 1) a two member manual screening of the references of 
each guideline, 2) a text-mining approach using Adobe Software, 3) a text-mining 
approach using EndNote, and 4) a text-mining approach using both Adobe Software 
and EndNote. As my knowledge and experience regarding systematic reviews and 
meta-analysis was limited, I did not perform the manual approach. 
In the approach using the Adobe Software, I used the search feature, with 
predefined keywords, on the references section of each guideline to identify the 
systematic reviews and meta-analysis, by their title. In the approach using EndNote, 
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first I imported the references of each guideline, including title and abstract, from the 
Web of Science to EndNote and then I searched the downloaded references using the 
search filters, also with predefined words, for paper title (first) and abstract (second).  
After applying the methodology of the study, I had an active participation in the 
analyses of the results obtained. Once the study was complete, a scientific paper was 
written. In the paper, I collaborated in the writing of the discussion section where I 
reviewed the characteristics and limitations of systematic reviews and meta-analysis. 
Although this project was almost concluded, it was suspended since other ideas 
for papers were deemed more relevant. 
 
2.1.4.2. Risk of substantial intraocular bleeding with non-vitamin K 
antagonist oral anticoagulants: Systematic Review and Meta-
analysis 
This was a study aimed at estimating the risk of intraocular bleeding associated 
with the use of Non-vitamin K Oral Antagonist Anticoagulants (NOACs) through a 
structured literature review and meta-analysis of phase III randomized controlled trials 
comparing NOACs with controls, which included active drugs and/or placebo.  
In order to identify the intended clinical trials, a search on the Medline and 
Cochrane Library was performed (inception to November 2014). The reference lists of 
systematic reviews and of each included study were also searched. After a 
comprehensive search, 17 studies were included and analyzed to extract data on 
intraocular bleeding events, using the RevMan 5.3.3 software, to synthesize the 
measures of effect.  
For this study, my contribution was limited to data analysis, which consisted in 
the identification of the arms (NOAC and control) of each phase III randomized 
controlled trial included and the total number of patients and intraocular bleeding 
events in each treatment arm.  
The paper that resulted from this study and of which I was designated co-author 
was published on the JAMA Ophthalmology (58).  
2.1.4.3. Risk of major gastrointestinal bleeding with non-vitamin K 
antagonist oral anticoagulants: Systematic Review and Meta-
analysis 
This was a study very similar to the study “Risk of intraocular bleeding with non-
vitamin K antagonist oral anticoagulants: Systematic Review and Meta-analysis”. The 
aim of this study was to evaluate the risk of major gastrointestinal bleeding associated 
with NOACs, also through a structured literature review and meta-analysis of phase III 
randomized controlled trials comparing NOACs with controls. For the purpose of this 
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study, the methodology applied was identical to the methodology applied in the 
previous one. 
In this study, besides data analysis, I was involved in the writing of the study 
paper in which I described the results of the search and the characteristics of the 
included studies and made a summary table with the information that was extracted 
during data analysis. 
At the end of my curricular training, this paper was being prepared for 
submission on the Alimentary Pharmacology & Therapeutics Journal. 
2.1.4.4. Risk of hematuria with non-vitamin K antagonist oral 
anticoagulants: Systematic Review and Meta-analysis 
This was a study in line with the previous ones. The aim of this study was to 
evaluate the risk of hematuria associated with the use of NOACs, comparing the 
number of events of hematuria in the different treatment groups (NOACs and controls) 
of the same phase III randomized controlled trials selected for the previous studies.  
For this study, as in the previous ones, I collaborated in data analysis, 
extracting data required to assess the risk of hematuria. Also, I was responsible for 
writing the introduction of a paper with the results obtained where I reviewed the main 
advantages of NOACs compared to the anticoagulants used before the introduction of 
NOACs, in terms of efficacy and safety, and discussed the uncertainty regarding the 
risk of hematuria for NOACs.  
However, this project was not concluded since flaws in the data extraction 
process, more specifically, in the identification of the hematuria events, were 
discovered.  
 
2.1.5. Other Activities 
 
2.1.5.1. Journal Club 
Every Wednesday, at 8 am, I attended the Journal Club, a meeting carried out 
by the investigation team of the CIC with the purpose of discussing recent findings in 
the field of neurology and neurosciences, usually clinical study reports. The discussion 
focused mainly on considerations on the design of the study, the potential therapeutic 
applications of the findings, and what prospects these studies could bring to the 
activities of the unit, amongst other topics. 
These morning sessions also served a double purpose, as they allowed for the 
team to discuss and share some information and problems about the functioning of the 
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sub-unit and to present and discuss clinical cases, in order to take advantage of the 
different backgrounds of the members of the team, to make the best clinical decisions.  
 
2.1.5.2. Wednesday Afternoon Meetings 
Every two weeks, on Wednesdays afternoon, I attended a meeting, held on the 
UFC, with all members of the team. These meetings had the purpose of sharing 
knowledge and perspectives on different topics, such as clinical outcomes, clinical trial 
methodologies, pharmacovigilance, quality management systems, quality control and 
de-identification of clinical data, clinical statistical monitoring, data monitoring 
committees, interim analyses, early stopping in clinical trials and risk management 
plans.  
Another purpose of these meetings was to share the ongoing or future projects 
of the different sub-units and/or team members to discuss and obtain feedback on the 
concept, methodology and other important aspects, in order to improve them.  
2.1.5.3. Data Entry and Drawing-up of a Database 
In parallel with the activities of clinical trials coordination I was invited to 
collaborate in a project of an investigator from CIC. The project was related to deep 
brain stimulation for Parkinson's disease and my collaboration consisted in the 
introduction of clinical data of patients who underwent surgery into a database, 
according to predefined specifications, for statistical analysis.  
Another activity that I have accomplished in parallel with clinical trials 
coordination was drawing-up of a database with demographics and other relevant data 
of patients participating in the REGISTRY study, to help in the management of study 
visits. The REGISTRY is a multi-center, multi-national observational study that focuses 
on the collection of clinical and biological data from patients with Huntington’s disease 
to provide an extensive repository of data to facilitate studies in this disease (59).   
2.1.5.4. Good Clinical Practice Course 
At the end of my curricular training in the UFC, I was invited by Professor 
Joaquim Ferreira to attend a course organized by the unit on GCP to strengthen my 
knowledge about this theme. The course had a duration of nine hours and focused on 
the principles of GCP, legislation and regulatory aspects associated with clinical trials, 
study protocol design, essential documents, responsibilities of the study sponsor, 
monitor and CRC, safety and Adverse Event (AE) reporting and practical aspects of 
conducting clinical trials.  
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2.2. Specific Training 
The main activity developed during my curricular training was clinical trials 
coordination. The role of the CRC is central to the successful conduct of a clinical trial. 
Many of the responsibilities of the research investigator are primarily the CRC’s 
operational responsibility, ranging from preparing the site for implementation of the 
clinical trial to managing patient scheduling and follow-up, recording and verifying data 
in CRFs, ensuring study supplies are properly inventoried, stored and recorded and 
keeping study files and records. 
During my training in clinical trials coordination, which lasted from January 2015 
to June 2015, I had the possibility to actively collaborate in almost all clinical trials 
ongoing in CIC. The clinical trials in which I was able to work are presented in Table 1, 
as well as the respective study phase and condition under treatment.   
 
Table 1. Clinical trials ongoing in CIC in which I actively collaborated. 
Clinical Trial Acronym 
(EudraCT Number) 
Study Phase Pathology 
EXPAND (2012-003056-36) III 
Secondary Progressive Multiple 
Sclerosis 
PROTEC (2013-001656-35) IV Relapse-Remitting Multiple Sclerosis 
EPOCH (2011-003151-20) II / III Alzheimer’s Disease 
LEGATO  (2014-000418-75) II Huntington’s Disease 
ISIS (2012-001831-30) II / III Familial Amyloid Polyneuropathy 
ACADIA (2007-003035-22) III Parkinson’s Disease 
MARGARITE ROAD (2013-
003390-95) 
III Alzheimer’s Disease 
ORATORIO (2010-020338-25) III Primary Progressive Multiple Sclerosis 
BIAL 311 (2009-011135-13) III Epilepsy 
DUODOPA (2008-001329-33) III Parkinson’s Disease 
SCARLET ROAD (2010-
019895-66) 
III Alzheimer’s Disease 
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The activities performed in each of the mentioned trials were in agreement with 
the enforcement stage of each clinical trial and are summarized in  Table 2. In the 
following sub-sections I discuss the main components of these activities.  
 Table 2. Study coordination activities performed in the different clinical trials.  
 Screening Randomization Treatment End-of-
Treatment 
Follow-up 
EXPAND 
  X X  
PROTEC X X X   
EPOCH X X X   
LEGATO X X    
ISIS X X X   
ACADIA   X   
MARGARITE 
ROAD 
  X   
ORATORIO   X   
BIAL 311   X   
DUODOPA   X   
SCARLET ROAD     X 
1Study visits imply preparation and conduction of study visits, eCRF completion, documents 
management and sample shipping. 
 
2.2.1. Initial Training Activities 
At the beginning of my curricular training in the CIC I received training on more 
logistical aspects of conducting clinical trials to be able to support the CRCs of the sub-
unit performing the specific activities of the different trials.  
2.2.1.1. The Study Documentation 
All information generated in the course of a clinical trial must be recorded, 
handled and stored, in order to allow the best conduct of the trial and the highest 
quality of the data produced, and to prove the trial was conducted in accordance with 
the protocol and all the applicable regulatory and ethical requirements. This information 
may be filed in the Investigator Site File (ISF) and/or in the patient’s file. 
2.2.1.1.1. The Investigator Site File 
The ISF is a file that is provided to the site at the site initiation visit and contains 
all the information that the site staff needs to carry out the clinical trial (60). Typically, it 
contains the investigation protocol and further amendments (when applicable), 
Clinical Trial 
Study Visit1 
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investigator’s brochure, updated and obsolete versions (if applicable) of the Informed 
Consent Forms (ICFs), clinical trial approvals, laboratory manual, CRF completion 
guidelines, delegation and subject logs, curricula of the research staff, training 
certificates, correspondence, and other documents related to the trial (60).  
During my curricular training, I had the opportunity to contact with ISFs from 
different studies. This allowed me to understand how these files may be organized. 
After understanding the organization of the ISFs of the clinical trials ongoing in CIC, I 
archived the documents that arrived at the sub-unit and identified if there was any 
missing documentation, in order to request it to the study sponsor. Besides archiving 
documents, I also helped in the completion of the subject recruitment, screening and 
confidentiality logs, which are documents of the ISF that must always be kept up-to-
date.  
2.2.1.1.2. The Patient’s File 
The patient’s file is a file containing the demographic and medical information 
about the patient, as well as all records generated in the course of the trial (60).  
Before each study visit, I reviewed the patient’s file to resolve any pending 
issues, such as signature of previous blood analysis reports or clinical evaluations, and 
to answer clinical queries. After the visit, I archived all the information generated in the 
visit, including medical records on AEs, concomitant medications and any relevant 
data, records from the collection of blood samples, vital signs and other complementary 
exams, identification of the medication retrieved and dispensed, and patient 
questionnaires. The archiving of that information is essential to complete the CRFs and 
to prove that procedures were performed. 
Regularly, I also verified if the patient’s file had all the information required as 
per protocol and, if not, I gathered the information and archived it in the right section of 
the file.  
 
2.2.1.2. The Study Procedures 
Any clinical trial requires the completion of several procedures during its course, 
including measurement of vital signs, performing electrocardiograms (ECGs), 
dispensing the investigational product and processing, storage and shipping of 
biological samples. These procedures are defined in the study protocol and must be 
performed according to the instructions given in the study guidelines and/or manuals 
(e.g. laboratory manual and CRF completion guidelines).  
 
Curricular Training Report: Clinical Trials Coordination in Neurology 
36 
 
2.2.1.2.1. The Interactive Response Technology (IRT) 
The IRT is a software that is used in clinical trials to enroll and randomize 
subjects, manage clinical trial supplies (drug tracking, dispensing and reconciliation), 
discontinue the patient’s treatment, set treatment completion and break blinding code 
(61). The most common types of IRT used in clinical trials are Interactive Voice 
Response Systems (IVRS) – automated telephone calls – and Interactive Web 
Response Systems (IWRS) – intuitive online systems (61).  
During my curricular training in the CIC, I had the opportunity to learn how to 
work with the IVRS/IWRS technologies ClinPhone®, Almac®, Bracket®, Endpoint® and 
Oracle®. First, I was explained about the functioning of such systems and then I 
observed the CRCs of the unit using them. After receiving this training, I was able to 
use these technologies autonomously.  
The use of any of these systems requires the confirmation of some information 
on the subject. Therefore, before using them, I identified that information and, after 
performing the assignments required, I received a confirmation, by email, and archived 
it in the patient’s file.  
2.2.1.2.2. Processing, Storage and Shipping of Biological Samples 
In the CIC, for the majority of the clinical trials, it is function of the CRC the 
processing, storage and shipping of blood and urine samples. 
The collection of blood samples is done using evacuated tube systems with 
interchangeable plastic tubes, all provided by the sponsor of each trial. The collection 
tubes, some with additives appropriate to a specific application, are differentiated by 
their color-coded stoppers and must be drawn in a specific order to avoid cross-
contamination of additives. Before each visit, I had to prepare the corresponding 
laboratory kits, which included identifying the collection and interchangeable tubes and 
completing the requisition forms with the subject number and demographic data. If any 
of the samples needed to be shipped frozen, I also requested the central laboratory of 
the study to send dry ice to the CIC on the day of the visit.   
During the collection of blood samples, I assisted the laboratory 
technician/study nurse, mainly by identifying the correct order of the collection tubes 
and agitating the samples to avoid hemolysis. After the collection of the samples, 
usually I needed to centrifuge them, according to the specifications given in the 
laboratory manual, and transfer the serum to the corresponding transfer tube(s). Some 
trials also required the preparation of blood smears. In these cases, I prepared the 
blood smears as described in the laboratory manual of the trial.  
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Regarding urine samples, some trials only required the samples to be sent if the 
urine analysis using a dipstick was positive. In these cases, I performed the analysis 
with the dipstick and sent the samples to the central laboratory if I found any abnormal 
result.  
After processing the samples, I prepared them to be shipped according to the 
study instructions, gathered the waybills and called the courier to send the shipment to 
the central laboratory of the study.  
2.2.1.2.3. Training on Technical Equipment for Clinical Trial Procedures 
Besides processing, storage and shipping of biological samples, the CRCs of 
the CIC are also responsible for performing some trial procedures, such as 
measurement of vital signs and performing ECGs.  
At the beginning of my training, I was explained on how to measure blood 
pressure, pulse, respiratory rate, temperature, weight and height. Thereafter, I was 
able to perform these tasks independently. Before performing any of these 
measurements, I had to consult the protocol of each trial to verify the specificities for 
the registration of each parameter. 
Also, I received training on how to use the electrocardiograph. I learned how to 
introduce the subject’s identification, place the electrodes, print the results and send 
the exams to the central team to obtain the clinical report. Although I have never 
performed an ECG autonomously, this training gave me the insight to certify the 
execution of this examination and intervene if the same was not being done properly. 
 
2.2.2. Setting Up a Clinical Trial 
Before any clinical trial can take place, several activities associated with 
identifying, qualifying, and activating an investigational site are carried out. The role of 
the CRC in these activities is crucial for the correct and successful implementation of 
the trial and for its proper conduction. 
2.2.2.1. The Feasibility Process 
Clinical trial feasibility is the process of evaluating the ability of an 
investigational site to conduct a particular clinical trial (62). Typically, the feasibility 
process includes two different approaches: a site feasibility questionnaire and a site 
qualification visit (62).  
The site feasibility questionnaire is targeted towards the future PI of the study 
and assesses the investigator’s experience, qualifications and interest in the research 
question, the availability of qualified staff to conduct the study, the suitability of the 
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patient population, the adequacy of site infrastructures, including the availability of any 
specialized diagnostic or therapeutic equipment, and the availability of time to conduct 
the trial (62).  
The site qualification visit, also called pre-study visit, is conducted to verify the 
capability of the investigator and of the investigational site to conduct the study (62). 
During this visit, the monitor of the study discusses with the PI and the CRC the 
investigator responsibilities, the basic fundamentals of the study protocol (study 
objectives, protocol-required procedures and eligibility criteria) and how that relates to 
the feasibility of recruiting potential participants, and the AE reporting, source 
documentation, and record retention (62). Usually, it also includes a visit to the site 
facilities, including the pharmacy, to confirm that the site meets the space requirements 
for the study and the required equipment is available (62).  
If the investigational site is eligible to conduct the clinical trial, the study team 
begins the preparation for the submission of the trial at the site. In the CIC, the CRC 
provides support to the study PI by preparing a letter to the president of the Ethics 
Committee requesting a review of the trial, obtaining the authorization from the 
Administrator of the Neurology Department and by reviewing the financial contracts. 
Unfortunately, I have not had the opportunity to follow this phase of the process 
of setting up a clinical trial. However, despite the feasibility questionnaires and the site 
qualification visits vary greatly from sponsor to sponsor, the CRC of the CIC showed 
me some feasibility questionnaires and taught me how to complete them and explained 
me the general workflow of the visits, as well as the submission procedures in place in 
the CIC.  
2.2.2.2. Investigator Meetings 
The investigator meeting is a meeting held before the beginning of a clinical trial 
between the site staff and the sponsor study team to discuss the trial in general 
(therapeutic area, procedures and associated documents) and the investigational 
medicinal product (63). The investigator meeting is an opportunity for the research 
team to learn what the clinical trial will be like, to discuss potential issues and share 
strategies and best practices from previous studies (63). 
During the period I was in the CIC, the CRCs of the sub-unit were able to attend 
some investigator meetings. As a trainee, I have not had the opportunity of attending 
any of these meetings. However, the CRCs explained me what was discussed and 
transmitted me the key knowledge that I was required to have to actively participate in 
the trials. 
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2.2.2.3. The Site Initiation Visit  
The site initiation visit is when the research team receives adequate training 
from the sponsor on the study protocol for the proper conduction of the trial (64). 
During this visit, the whole study team and the sponsor discuss several aspects 
regarding the trial, including study design, objectives, eligibility criteria, procedures and 
access to suitable patient population, requirements for research sample processing 
and shipping, applicable regulations and GCP requirements, informed consent 
requirements, AE reporting, drug accountability, data forms completion, regulatory 
documents and study file organization (64). The site initiation visit is also an opportunity 
for team members to clarify their doubts concerning the trial (64).  
The initiation visit is the last step before the study site is activated for enrollment 
by the sponsor (64). During my training in the CIC, I had the opportunity of participating 
in three site initiation visits. In these visits, I was able to gain an in-depth understanding 
on the trials and their procedures, and to know the study monitors. I also supported the 
monitors of the study in organizing the study cabinet, archiving documents in the ISF 
(correspondence that had already arrived at the site, delegation signature log, visit log 
and other essential documents) and verifying laboratory kits and other study 
equipment. After the visits, I also requested signatures whenever a member of the 
research team had not attended the visit.  
 
2.2.3. Running a Clinical Trial  
Once all the relevant approvals are in place, all documentation has been 
finalized, and the site has the appropriate and required training on the protocol, the trial 
can begin. 
2.2.3.1. Preparing the Study Visits 
Prior to each study visit, the research team must be prepared for all known and 
unknown tasks that may need to be completed as per protocol. A good preparation of 
the study visits is essential to avoid protocol deviations and to increase the quality of 
the generated data. 
Most visits require a diversified clinical evaluation, with several clinical 
assessment procedures and involving several team members. The first step before a 
trial visit is to schedule all required procedures with all team members and the patient. 
When scheduling the evaluation procedures and the visit itself I remembered the team 
members about the tasks to be completed and informed patients on where the visit was 
going to take place and how long it would take, and any special instructions the patient 
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should follow prior to the visit. This was important to ensure protocol compliance. Once 
the visit was scheduled, a follow-up contact, usually in the form of a phone call, to the 
patient was performed to reinforce the requirements of the study and further explain 
important details of the upcoming visit. 
Before preparing any trial visit, I had to review the protocol of the trial, with 
special attention to the core assessments of the concerned visit, as well as the 
patient’s file, in order to be able to resolve pending issues and/or those that could arise 
during the visit. After that, I prepared the visit, which usually included completion of 
required physician orders, such as the medication prescription form, preparation and 
provision of laboratory kits to the appropriate clinical team to draw the samples, 
preparation of patient questionnaires and of worksheets and checklists with all visit 
procedures indicated per protocol to aid investigators conducting the visit and to 
ascertain that required data was collected.  
When preparing a visit, I also had to consider the possibility of the patient 
deciding to withdraw from the study or to be withdrawn by the study investigator due to 
AEs or any other clinical relevant reason. Therefore, before each visit, I had to review 
the end-of-study visit procedures and to know where the visit items were to be readily 
available, if these situations happen. 
2.2.3.2. The Study Visits 
Usually, all clinical trials have a screening visit, in which the study investigator 
determines if the patient is eligible to participate in the trial; a randomization visit, where 
the patient is assigned to the study treatment(s); the treatment visits, aimed at 
assessing the effect of the study treatment(s); an end-of-treatment visit, to conclude the 
participation of the patient in the trial; and a follow-up visit, carried out to monitor the 
safety of the patient. The course of each visit is determined by the study protocol. 
2.2.3.2.1. The Screening Visit 
Before any study-specific procedures or evaluations can take place, the patient 
must sign and date the ICF, after a comprehensive discussion with the investigator of 
the study. During this process, I supported the investigator by clarifying any questions 
regarding the trial that had arisen during the discussion and by explaining the logistic 
aspects of the trial to the patient, such as where were the different visits/assessments, 
how was transportation handled and how were expenses reimbursed. I also made a 
copy of the signed ICF to deliver to the patient. 
Once the consent form had been signed by all applicable parties, I registered 
the patient in the IVRS/IWRS system to obtain the patient’s screening number, which 
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identified him/her in the study. After registering the patient, I performed the study 
procedures that could be done at the same day of the visit. These usually included 
measurement of vital signs, performing an ECG, processing of laboratory samples and 
delivery of patient questionnaires. Besides performing these procedures, I also 
scheduled the ones that could not be done at the visit (e.g. ophthalmology exam, 
pulmonary function test, dermatology assessment), always considering the window 
timeline required by the protocol. At the end of the screening visit, I gave the patient an 
identification card identifying him/her as a participant in the clinical trial and containing 
trial site contact information (including direct telephone numbers) to be used whenever 
necessary.  
In this visit, it is important to collect the medical history of the patient in a 
detailed and thorough way, as well as other relevant clinical data, such as 
demographics, as established in the study protocol. To ensure these data were 
collected, before each visit, I prepared checklists and worksheets identifying the 
information to be recorded in the medical file of the patient. 
If the patient did not meet one or more criteria required for participation in the 
trial, after signing the ICF, the patient was considered a screening failure and I reported 
it in the IVRS/IWRS system. 
During my training, I performed five screening visits and supported the other 
CRC’s performing 13 visits. Of these 18 screenings, four were considered screening 
failure. 
2.2.3.2.2. The Randomization Visit 
The randomization visit corresponds to the treatment initiation. After the 
investigator of the study confirmed that the patient met all inclusion criteria, I performed 
his/her randomization to one of the study treatment arms using the study IVRS/IWRS 
system. Once the investigational product has been dispensed by the pharmacy, I gave 
it to the patient and explained him/her on how to take/administer it. Usually, the first 
dose of the investigational product was taken/administered in the CIC to monitor the 
safety of the patient.  
At this visit, and when applicable, I also delivered to the trial patient a study 
medication diary to record information about medication use. Therefore, I had to 
instruct the patient to record the study drug intake, according to the instructions given 
in the study protocol/study medication diary manual.  
In addition to the randomization of the patient, I performed and/or helped to 
perform the other specific procedures of the visit (measurement of vital signs, 
performing ECG, processing, storage and shipping of laboratory samples and delivery 
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of patient questionnaires) and scheduled the ones to be performed outside the CIC, as 
specified in the study protocol. 
In the scope of my training, I had the opportunity of performing five 
randomization visits and of providing support to the CRCs in 12 other visits. 
2.2.3.2.3. The Treatment Visits 
The course of each treatment visit is established by the study protocol and is 
related to the purpose of the trial. Despite the differences between treatment visits of 
the same trial and between visits of different trials, there are a set of activities that are 
responsibility of the CRC and are similar for all treatment visits. The main differences 
are regarding scheduling of specific assessment procedures (e.g. neuropsychological, 
ophthalmology, pulmonary function and dermatology).  
Therefore, in any treatment visit, I remembered the study investigator on the 
information that should be recorded in the patient’s medical file, measured vital signs, 
assisted in performing the ECG and delivered the patient questionnaires to the patient. 
In this later step, I instructed the patient on how to complete the questionnaires and, 
before the end of the visit, I checked if they were correctly answered to avoid missing 
data. If the visit required the collection of biological samples, I processed the samples, 
stored the ones to be left in the CIC as backup and sent the others to be analyzed in 
the central laboratory.  
Also, I registered the visit in the IVRS/IWRS system and ordered a medication 
resupply to dispense new medication to the patient. Before making the dispensing, I 
received the returned medication and made the medication reconciliation to assess 
compliance. After that, I delivered it to the patient and reinforced the indications on how 
to take it and reminded him/her to bring the unused medication and the empty 
packaging on the next visit. Regarding the study medication diary, I collected it and 
delivered a new one.  
During the treatment period, it is frequent that ICFs are reviewed. Every time a 
new addendum was made to the ICF, I reminded the investigator to explain to the 
patient the change(s) and to give him/her the new version to be signed and dated. 
Then, I made a copy of the new signed ICF and delivered it to the patient.  
In my training, I performed treatment visits for all clinical trials in which I was 
engaged, except for one (Table 2). 
2.2.3.2.4. The End-of-Treatment and the Follow-up Visits 
An end-of-treatment visit is scheduled when the patient has completed the 
treatment period, as defined by the protocol of the study. After the end-of-treatment 
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visit, usually one month later, a follow-up visit is performed. The follow-up visit is 
conducted mainly to collect information on AEs. 
Sometimes, it happens the patient discontinues the trial investigational product 
prematurely. In this case, the visit end-of-treatment – premature discontinuation is 
scheduled shortly after the patient has discontinued the trial investigational product. 
Patient discontinuation can be due to progression of disease, unacceptable toxicity, 
AEs, non-compliance with the study protocol, investigator decision, pregnancy or 
withdrawal of consent.  
During the six months I was in the CIC, I had the opportunity of performing one 
end-of-treatment and two follow-up visits. In the end-of-treatment visit, besides 
performing and scheduling the usual procedures, I made the discontinuation of the 
patient in the IVRS/IWRS system, retrieved all the investigational products that the 
patient had, collected the study medication diary and performed the final drug 
accountability. In the follow-up visit, I performed the procedures specified in the 
protocol that were responsibility of the CRC (measurement of vital signs and 
processing, storage and shipping of laboratory samples). 
 
2.2.3.2.5. After the Visit 
After each visit, I gathered all the information collected during the visit as well 
as the information that was generated. This information was then reviewed to ensure 
that all necessary data was collected and to check its consistency and transcribed 
and/or uploaded into the study CRF.  
CRFs are data collection tools, provided by the clinical trial sponsor, that are 
designed to record all of the protocol-required information to be reported to the sponsor 
on each trial participant (65). The CRF completion allows the capture, review, 
management, storage, analysis, and report of data, in a systematic basis (65). There 
are two types of CRFs used in clinical research – paper CRFs and electronic CRFs 
(eCRFs) (65). During my training, I had the possibility of working with both types of 
CRFs. However, I preferred working with eCRFs as they have built-in edit checks 
tagged to each data field, as well as to the CRF as a whole.  
The majority of the clinical trials being conducted in the CIC during my training 
used eCRFs. Before using any of these systems, I received training from the CRCs of 
the sub-unit on how to access the CRF, make data entry, validate and correct data, 
and answer queries, according to the eCRF completion guidelines. The most 
commonly used systems in my training were Inform™, Think Trial™, Viedoc™, 
QCAT™, Medidata Rave™, BioClinica Express™ and RDC Onsite™. In some of them, 
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I had to transcribe data present in the source documents (e.g. RDC Onsite ™ and 
Inform™) and in others I had to directly upload data (e.g. QCAT™).  
After transcribing/uploading the data on the CRF, I archived all source 
documents in the patient’s file and sent the ECG, if performed, from the 
electrocardiograph to the central reading laboratory, by phone line. Also, if the 
investigator had reported an AE or a Serious Adverse Event (SAE), I verified the 
completeness of the report to be sent to the sponsor, sent it and transcribed it into the 
CRF, and made the follow-up of the event.  
2.2.3.2.6. Closing Out the Clinical Trial and Archiving Essential Documents 
A close-out visit occurs once the patients are no longer being dosed and all the 
data have been collected, including complete follow-up of AEs/SAEs and resolution of 
all outstanding queries (66). At this time, the study database is locked and ready for 
statistical analysis (66).  
The purpose of this visit is to assure that the study is complete, all study 
supplies and investigational agents are returned to the sponsor, the study 
documentation is in place and data is accurate, and to discuss the requirements for 
retention of study materials (66). Therefore, it is important that the investigator and the 
other study team prepare for the closeout visit.  
During my training, I was able to collaborate in the preparation of one close-out 
visit. This involved reviewing the study files for completeness and accuracy, 
consolidating all records into one set of study files, completing and having the 
investigator reviewing and signing all CRFs, assuring that the subjects' medical records 
and clinic charts were available for the monitor to verify data and address queries, 
having all subjects' signed ICFs available for review and storage with the study 
records, resolving any outstanding discrepancies identified on previous periodic site 
visits, amongst others. In this visit, the CRC should make sure that the sponsor returns 
all study supplies and medications, shipment receipts are complete and accurate and 
copies are placed in the regulatory binder.  
After the close-out visit, all essential documents should be archived. Essential 
documents are “those documents that individually and collectively permit the evaluation 
of the conduct of the trial and the quality of the data produced and show whether the 
trial is, or has been, conducted in accordance with the applicable regulatory 
requirements” (25). These documents include the ISF and participant CRFs and source 
documents (25). The study documentation must be retained for at least 5 years after 
the conclusion of the trial, as defined in the Decree-Law 102/2007 of April 2nd (34), or 
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for 15 years, as defined in the ICH GCP E6 guidance (25), and, during that period, 
readily available to the regulatory authorities on request (25,34).  
2.2.4. Other Activities of a Clinical Research Coordinator 
Besides preparing and conducting study visits, there are several other activities 
that must be performed in a clinical research center to ensure the proper conduction of 
clinical trials.  
During my training in the CIC, I supported the CRCs of the sub-unit clarifying 
outstanding issues and new updates of the studies together with the study monitors, 
replying to e-mails from the investigators, monitors and other parties involved in the 
studies, and delivering to the investigators reports of suspected unexpected serious 
adverse reactions and other study documentation to be signed by them. Also, I 
updated the ISF archiving correspondence, newsletters and other study information, 
and filling the patient identification log, the screening log and the sample logs on an 
ongoing basis.  
After data entry, queries may be generated. Queries are any errors, omissions, 
or items requiring clarification or changes to the CRF that are detected during the data 
entry and verification process, by computer edits or during data analysis (67). The 
prompt resolution of queries is important so that the analysis of the data is not 
compromised. Therefore, regularly I checked the CRFs of the trials to verify if there 
were any pending queries and tried to resolve them. Sometimes, the complexity of the 
queries required me to contact the study monitors. If the queries had to be resolved 
with urgency, usually, the study monitor sent an email identifying the open queries and 
with some guidance to answer them.  
Regularly, I also had to check the material stock of each clinical trial in order to 
ensure that the material required for each visit was available when needed. Therefore, I 
checked the laboratory kits that were running out or that were expiring soon, ECG 
electrodes, patient’s diaries and other materials specific to each clinical trial, in order to 
ask the sponsor for replacements. 
Furthermore, once a month, I downloaded the freezer temperature logs and, 
when there was a large number of samples in the freezer, I made a list identifying the 
samples that were stored to send the samples that could be sent and left only those 
which had to stay as backup.  
In the CIC, every Friday a calendar with the following week’s visits, indicating 
the protocol number, the number of patients and the scheduled times, was sent to the 
pharmacy, the study nurses and the psychologists to ensure the proper conduction of 
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the trial visits. During my curricular training, I was responsible for preparing the 
calendar and sending it to the appropriate team members. Besides that, every Friday I 
also identified the next week visits that required samples to be sent frozen and asked 
the central laboratory to send dry ice for the day of the visit.  
2.2.5. Periodic Monitoring Visits 
The most significant interactions between the CRC and the study sponsor occur 
during site monitoring visits. Throughout the course of a clinical trial, several periodic 
monitoring visits are carried out to assess the progress of clinical trials, verify 
adherence to the study protocol, check if the reported data is complete and consistent 
with the source documents, and ensure patient safety and compliance with ethical and 
regulatory requirements (66).  
During my training in the CIC I had the opportunity of actively participating in 
periodic monitoring visits of two clinical trials. Before each visit, I had to complete all 
necessary CRFs, confirm that SAE forms have been submitted and were available for 
review, obtain medical records for CRFs to be reviewed, organize study file documents, 
confirm that signed ICFs for all enrolled participants were available and review if all 
pending issues from the last monitoring visits were resolved. Also, I gathered all doubts 
regarding the trial (e.g. completion of CRFs, performance of specific procedures) to 
clarify with the monitors of the studies. During the visits, I assisted the monitors 
understanding the reported data and, after the visit, I discussed with them the findings 
from the monitoring and started answering them.  
2.2.6. The Most Involving Clinical Trial – The Expand Trial 
 
The Expand trial, a multicenter, randomized, double-blind, parallel-group, 
placebo-controlled variable treatment duration study evaluating the efficacy and safety 
of siponimod (BAF312) in patients with secondary progressive multiple sclerosis, is a 
phase III clinical trial sponsored by Novartis. The study’s primary objective is to 
demonstrate the efficacy of siponimod relatively to placebo in delaying the time to 
confirmed disability progression as measured by the Expanded Disability Status Scale 
(68). The secondary outcome measures include the efficacy of siponimod relatively to 
placebo on mobility and leg function and in reducing the increase in CNS lesion 
volume, impact of multiple sclerosis on the individual’s walking ability and number of 
AEs, amongst others (68).  
Although I have participated in almost all trials ongoing in the CIC at the time of 
my curricular training, the Expand trial was the study in which I was more active and 
autonomous. When I started collaborating in this trial, the patients were already in the 
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treatment phase. Therefore, I received training on this clinical trial (procedures and 
assessments, requirements for research sample processing and shipping, data forms 
completion and study file organization) from the previous CRC responsible for the trial. 
The Expand trial was a relatively complex trial due to the number of 
procedures/assessments required by the protocol and the number of team members 
involved. Besides preparing and conducting trial visits, providing backup to the 
investigator, completing the eCRF and answering queries, receiving monitoring visits 
and managing documentation related to the trial, I had to schedule all 
procedures/assessments, always considering the window timeline established by the 
protocol, and handle transportation requests.  
Since this trial had a lot of procedures/assessments and a specific order to 
carry them out, a thorough organization was almost mandatory. Therefore, I developed 
checklists and worksheets with all visit procedures indicated per protocol for each visit 
and identifying the order to be followed. This was important not only to ensure protocol 
compliance but also to plan the visits to be as time efficient as possible, since long 
visits were very tiresome for the subjects.  
2.2.7. Coordination of Observational Studies 
My activities as a CRC were developed in the context of clinical trials. However, 
during the time I was in the CIC, I had the opportunity of actively collaborating in the 
coordination of observational studies. An observational study is a study where the 
assignment of the patient to a particular therapeutic strategy is not decided in advance 
by a trial protocol but falls within current practice (31). 
During my training, I collaborated in the introduction of data into the eCRF of an 
observational study on idiopathic cervical dystonia. However, the study in which I 
participated more thoroughly was the REGISTRY study. In this last study, I helped the 
CRC scheduling study visits according to the availability of the study investigators, 
preparing and conducting study visits, providing support to study patients completing 
self-report questionnaires and preparing and shipping biological samples to the central 
laboratory.  
2.2.8. Site Monitoring Visit 
 Within the scope of the REGISTRY study, I was able to accompany a site 
monitoring visit. The REGISTRY is a project of the European Huntington’s Disease 
Network, a Europe-wide network of professionals and people affected by Huntington’s 
disease (59). As a part of this network, the HSM has an active participation in this 
study. The HSM is the Portuguese language area coordinator of REGISTRY, being 
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responsible for coordinating and monitoring the study in all Portuguese centers 
participating in it. 
 One of the CRCs of the CIC also accumulates functions as monitor of this 
study. The monitoring of the REGISTRY is divided into two components, on-site 
monitoring and remote monitoring. The remote monitoring is performed to data that 
does not have source documents and, therefore, is directly introduced in the eCRF, 
and is based on the verification of the consistency of the data entered. On-site 
monitoring, on the other hand, is performed whenever data is transcribed into the 
eCRF. 
 The site monitoring visit I was able to accompany was performed in a local 
hospital in Lisbon. During this visit I helped the monitor of the study verifying if previous 
queries where answered properly and if the protocol was being followed and reviewing 
the study documentation to identify data entry errors and missing data in the patients 
records or eCRFs. Whenever data entered was not in accordance with source 
documents or data was incomplete, I helped the monitor of the study generating 
queries to be reviewed by the investigational team. 
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3. Discussion 
Clinical trials are a key part of the development of new health interventions as 
they allow researchers to demonstrate the efficacy and safety of a new medicine or 
treatment in humans, which is a prerequisite to get regulatory approval (69). 
Considering the importance of clinical trials, for the second year of my Master’s 
degree in Pharmaceutical Biomedicine, I decided to enroll in a curricular training in 
clinical trials coordination. The characteristics of the UFC, host institution of this 
training, allowed me to participate in several activities relating to different stages of the 
development of new health interventions, which made this experience a very enriching 
one. 
The CIC is a very well organized research unit with several years of experience 
and with dedicated and qualified staff in the coordination of clinical studies, who were 
always eager to share their knowledge and experience in clinical research and to help 
me deepen my knowledge and became a better professional. 
When I started my training in the CIC, the research team was experiencing a 
reformulation since one of the CRCs left the team. Therefore, right from the start of the 
training, I was asked to assume a very active role in the coordination activities, which 
was quite complicated to me as I had no previous experience. At the beginning it was 
difficult to understand how to handle with study documentation and the order and 
timing of the different study procedures, to identify the research team of each study and 
to apply some study procedures. However, I always felt supported by the other CRCs 
of the CIC who helped me overcoming these difficulties and clarified my doubts. First, I 
was mainly responsible for archiving the study documentation and processing and 
shipping biologic samples. As the training evolved, I was able to start performing 
activities that required more responsibility, such as managing patient visits by myself, 
communicating directly with the monitors of the trials to resolve outstanding issues and 
making reimbursements of patients’ expenses. 
During my curricular training in the CIC, there were 22 clinical trials and 10 
observational studies ongoing. Although I have not participated in all of them, I was 
able to work in different studies. This was a unique opportunity to contact with protocols 
with different levels of complexity, study designs and procedures, from distinct 
sponsors and in several pathologies. I learned a lot from reading the study protocols 
and from applying their procedures and I became more proficient in understanding this 
type of documents. This training experience was even more enriching as I was able to 
participate in the coordination of trials from different phases. In fact, the only trial phase 
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I was not able to work in was phase I. Also, this was an opportunity to consolidate my 
background knowledge on the pathologies I worked, alongside the current available 
treatments. 
During my training in the CIC I had the chance of working with different types of 
medications, biologics and chemically derived drugs. This was an important aspect of 
my training as I was able to see and understand the different requirements for handling 
these types of medications and the procedures for the preparation of patients before 
the administration and for the administration of the drug. Also, I noticed the different 
types of AEs that may occur with each type of medication and the specificities of the 
data to be reported. 
A CRC is someone who is constantly communicating with different stakeholders 
in clinical research, from the investigators and remaining site staff, to the study 
monitors and other representatives of the study sponsor, and who ensures the 
completeness, consistency and integrity of the data reported, the good 
progression/flow of the trial, and protocol compliance. Performing these activities was 
very important for me to improve my communication and organization skills and to 
become more attentive to detail, focused and more stringent in terms of quality of work. 
Also, this training allowed me to improve my ability to work in teams. Every day we had 
appointments of more than one trial, with several procedures and a lot of information to 
manage. Therefore, we had to work as a team to ensure everything was done right. 
Coordinating clinical trials in the CIC was a constant challenge and learning 
experience. The high number of clinical trials and observational studies ongoing in the 
CIC required me to perform several different procedures, which I think was a great 
opportunity to complement the knowledge acquired in each study. Also, the 
unpredictability of dealing directly with patients was very important for my professional 
growth. During the six months I was in the CIC, there were many the situations where 
every procedures were scheduled and all things were prepared and the patient did not 
show up or just canceled the visit the day before because he/she did not want to come 
or was not feeling well, making it difficult to re-scheduled everything within the 
therapeutic window of the visit. However, with the experience of the CRCs of the CIC, I 
learned how to proceed in these situations and, in the end of my training, I was quite 
autonomous to resolve these problems. 
The training in clinical trials coordination was also very rewarding for me as I 
could see and apply the knowledge acquired previously in the Bachelor’s Degree and 
in the first year of my Master’s Degree and complement the concepts learned. It was 
very motivating for me to see the applicability of all the subjects I learned during the 
last four years in a real world context and to look at things from a new perspective, the 
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on-the-job perspective. This complementarity makes me feel that I am even more 
prepared to become a professional of clinical research. 
 During the training in the CIC, I was able to closely experience the main 
hindrances of running clinical trials in neurology. As mentioned above, clinical trials in 
neurology have very restrictive inclusion criteria and exhaustive evaluation 
processes/tools and lack of objective effect measures (16). As the HSM is a central 
hospital, the investigators from the CIC see many patients every day, including de 
novo; still, for some clinical trials, it was difficult to include patients and reach the 
agreed number of participants. Even after a pre-selection of patients using databases 
with clinical data, it was difficult to identify those that met the restrictive inclusion 
criteria. Also, for almost all trials in which I worked, patients had to stay in the CIC for 
several hours or come to the CIC and other institutions involved in the trial several 
times, due to the exhaustive evaluation processes and tools. For some of the trials, 
patients had to stay in the CIC during the whole morning or even the whole day. 
Another reality I could experience was the lack of objective measures of the effect of 
drugs. The vast majority of the clinical trials in CIC used only evaluations that included 
level of cognitive or physical function, which can be subject to variation in reporting by 
patients or investigators. This was quite interesting for me as I saw in the field what I 
learned in theory, by reading papers and other publications. 
 The main difficulty I felt in this training was to manage clinical trials in which I 
was not involved from the beginning. It was hard for me to realize the dynamics of the 
study visits, what procedures should be done first, in what substudies the patients were 
participating, and answer queries and solve other issues regarding the study before I 
started working on it. Another difficulty I felt was to conciliate all the procedures that 
had to be done for the study visits, within the given therapeutic window, due to the 
different availability of the involved parties. Contrary to what I first thought that would 
be my main difficulty, the contact with the patients was pretty easy. I always felt 
comfortable talking with them and performing the study procedures. 
 Besides the achievements I made, I think there was an important gap in my 
training. In the CIC, the CRC is responsible for the coordination of the submission 
process of the trial documentation to the Ethics Committee and the Administration 
Board of the HSM and the Administrator of the Neurology Department. Although I was 
explained about this process, I was not able to participate in it, which makes me feel 
that I am not prepared to do this task by myself.  
 With this training I realized that the conduction of a clinical trial is a very 
demanding task that requires strict adherence to the study protocol and a thorough 
logistics preparation and that being a CRC is much more than ensuring protocol 
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compliance and quality of data. The CRC plays a pivotal role in clinical trials by 
managing the anxieties and expectations of patients with the clinical research they are 
enrolled in, assisting study monitors and facilitating the communication between 
investigators, patients, monitors and other sponsor representatives.  
 After the 6 months of training in clinical trials coordination, I strongly believe that 
I met all the objectives I have set for this training. From preparing and conducting study 
visits, measuring vital signs and processing and shipping of biological samples, to 
completing CRFs, answering queries, using IVRS/IWRS systems, assessing 
compliance with the study medication, archiving study documentation and monitoring 
data quality, I learned to perform all these activities. After this training, I believe that I 
am well prepared to become a CRC. Also, I believe that starting my career in clinical 
trials coordination was a very good basis to perform other functions in clinical research. 
 The opportunity of experiencing the activity of monitoring of clinical trials was a 
good complement to my training. In the site monitoring visit that I participated in, I 
learned different methodologies of work, including different ways of organizing a 
research site and the study documentation, learned how to do source data verification 
and practiced data quality control. The possibility of seeing how other research teams 
work was very enriching as I could find ways to improve my working methods to be 
more efficient and do things better. 
 Despite the importance of coordination of clinical trials, I cannot devalue the 
contribution of all the other activities carried out during this 10 month training for my 
personal and professional growth. From drawing-up a quality control plan, receiving, 
validating and processing of spontaneous reports of ADRs and collaborating in the 
writing of scientific papers, to the courses I was able to attend and all the other 
activities I have done, I consider that I have gained a very good background knowledge 
to start my professional career.  
 The data management activities I was engaged in were very important as I had 
no previous theoretical and/or practical knowledge on this matter. During my academic 
education this was a subject that was not explored in detail and, therefore, I had little 
knowledge on the matter. This training provided me the opportunity of learning what is 
data management, how is it done and why is it important. The most interesting thing in 
this training was to see data quality control applied within the scope of data 
management activities. Also, it was very important for me to understand the relevance 
of collecting complete data in clinical studies, as missing data may lead to the 
exclusion of a research participant from data analysis, compromising the assessment 
of the effect of the intervention under study. I believe that accomplishing the training in 
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data management before starting the activities of clinical trials coordination made me 
more demanding in terms of data collection and reporting.  
 My training in the URFLVT was also a very interesting experience as I could 
realize the importance of pharmacovigilance. All medicinal products are subject to 
several clinical trials to assess their quality, efficacy and safety before being authorized 
(70). However, clinical trials have several methodological limitations that do not allow 
the obtainment of a comprehensive knowledge of a drug safety profile (70). In fact, the 
experimental environment is significantly different from that in which the drug will be 
used in clinical practice (70). Therefore, it is essential to have oriented structures for 
drug safety monitoring once drugs are placed on the market and start being used on a 
large scale by patient groups in which they have not been investigated and in very 
different conditions from those in which they were developed.  
 Although my training in the URFLVT was short, it was enough for me to realize 
the background knowledge that performing pharmacovigilance activities requires. 
Being engaged in pharmacovigilance activities requires a deep understanding and 
knowledge on the legislation in force, medicines available in the market (indication, 
dosage strength, formulations, …) and diseases. In my training, I learned how to 
validate reports according to pre-specified criteria, how to introduce data in Portal 
RAM, how to send data to the SVIG and how to make requests for additional 
information. 
 One of my main difficulties during this training in pharmacovigilance was to 
classify ADRs as described/non-described, according to the information of the 
summary of the product characteristics, since it was necessary an adequate knowledge 
to verify whether a reported term was equivalent to the ADR or not. Therefore, I always 
had to confirm with the two pharmaceuticals of the unit if my classification was correct. 
Also, I had difficulties coding ADRs using the MedDRA as I had to use the term that 
was closest to that reported and that term was not always available in the dictionary. In 
turn, as the training progressed, I learned from my mistakes and became more 
proficient coding ADRs. Due to my limited knowledge, mainly regarding the specificities 
of medicines (dosage strength and formulations), I also felt difficulties identifying the 
questions to address to the reporters to request for additional information. However, 
with the experience gained during the training, I am now more capable to do those 
requests.  
Despite the mentioned difficulties, I consider that this training in the URFLVT 
was very important. I learned, as a professional and as a citizen, the importance of 
doing a good report of a suspected ADR, mainly the importance of providing the largest 
possible amount of information about the ADR, the suspected drug and any 
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concomitant medication and diseases, to better assess the probability of the drug 
causing the ADR. Also, learning to code medical information with the MedDRA was an 
added value for my training, as working with the MedDRA is almost mandatory in the 
pharmaceutical field and I have never had that chance before. 
As for medical writing, this was a great opportunity for me to improve my writing 
skills. I had the opportunity of collaborating in several different research projects, from 
applying their methodologies to writing some parts of their papers. I learned how to 
write in an objective, clear and scientifically correct way and I could see the evolution of 
my writing abilities over the projects in which I participated in. The medical writing 
activities I engaged in also gave me the unique opportunity of publishing, as a co-
author, in a peer reviewed journal. 
Besides the activities I was able to carry out during this 10 month period, I also 
have to mention the great opportunity that was being able to attend the meetings of the 
research teams of the CIC and UFC and all the courses facilitated by them. The 
discussion of research papers, mainly their methodologies and limitations, and of 
research projects of some members of the group was a unique opportunity for me to 
deepen my knowledge on these subjects. Also, the discussion of recent papers allowed 
me to be aware of what was being done in clinical research in neurology, what was 
being discovered and what was being made to increase the quality of life of people 
suffering from neurological diseases. The courses I attended were an opportunity for 
me to deepen and refine the knowledge previously acquired in the Bachelor’s and 
Master’s Degrees. 
Considering the above, I believe that the characteristics of the host institution, 
the UFC, were the main factor that most influenced the success of my training. Its well-
defined structure, as well as the professionals that constitute the research group, who 
have a deepen knowledge in clinical research and a strong desire to teach and share 
their knowledge, and the working principles and values of the group, mainly the 
cooperation and teamwork, were fundamental for me to reach my objectives and 
successfully finish my training.  
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4. Conclusion 
My curricular training in the UFC was a very rewarding and enriching 
experience. I had the opportunity of participating in several research projects, from 
coordinating clinical trials to performing data management, pharmacovigilance and 
medical writing activities, and working with different groups, with very different 
backgrounds and experiences. 
This training in the UFC allowed me to refine and complement the knowledge 
previously acquired in the Bachelor’s and in the Master’s Degrees, mainly on GCP, 
clinical drug development and drug lifecycle, medicines regulation and ethics in clinical 
research. It was also an opportunity for me to develop hard and soft skills that will help 
me to become a better professional. I improved my organizational and communication 
skills and ability to focus and learned to better work in teams and plan things. As my 
training evolved, I engaged in more activities and responsibilities, which helped me to 
become more autonomous and more confident with my work.  
After this training, I can say that I meet all my primary objectives. The possibility 
of participating in the coordination of clinical trials of different phases and in several 
neurological diseases allowed me to learn and practice a broad range of activities and 
to increase my knowledge regarding clinical research. Working in a team such as the 
CIC gave me a real insight about the environment of clinical research and was an 
opportunity to understand the functioning of an organized and recognized clinical 
research center.  
 Regarding the secondary objectives, I learned how to do clinical trial monitoring, 
become capable of receiving, validating and processing spontaneous reports of ADRs, 
developed skills in clinical data management and improved my medical writing skills. 
With these activities, I got a perspective on the process of the clinical development of 
new medical products, besides the conduction of clinical trials. Also, I could understand 
how these different fields relate to each other. 
Overall, I would say that my training has become more than I have ever 
expected. Every day was a constant learning experience and a challenge that made 
me grow up professionally and personally. I believe that with this training I am well 
prepared to start my professional career and to perform different functions in clinical 
research. 
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